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 ABSTRACT 
 
Breast cancer (BC) figures as the most frequently diagnosed and the leading cause of 
cancer-related deaths among women worldwide. Despite considerable progress has been 
made in cancer detection and therapy assignment, several BCs become resistant to 
therapy and, moreover, a considerable proportion of patients develops metastasis during 
therapy or experiences relapse. 
Growing body of evidence indicates that alterations in tumour metabolism are linked to 
therapeutic resistance, tumour relapse and dissemination. These altered metabolic traits 
are caused by genetic alterations and environmental factors.  
The most frequently mutated gene in BC is the tumor suppressor TP53, a well-
characterized transcription factor, which plays a central role in cellular homeostasis and 
prevention of tumour growth. In BC missense mutations occur very often in its DNA 
binding domain, providing neomorphic mutant p53 proteins that lose the wildtype onco-
suppressive functions and acquire instead new oncogenic properties (Gain-of-Function). 
Indeed, mutant p53 proteins establish aberrant interactions with different transcription 
factors, thus inducing oncogenic transcriptional programs and metabolic 
reprogramming.  
Our previous work outlined a mutant p53 driven signature that promotes aggressiveness 
in BC in which DEP domain containing 1A (DEPDC1A) emerged as an important 
mediator of migration and invasiveness (Girardini et al., 2011). DEPDC1A expression 
is almost undetectable in normal cells, but it is overexpressed in different cancers and its 
overexpression is associated with poor prognosis. DEPDC1A is a transcriptional 
cofactor that exists in two different splice variants V1 and V2, but its role in 
oncogenesis, as well as in a physiological context, remains elusive.  
 
Here we show, through a high-throughput transcriptional analysis, that DEPDC1A is 
able to impinge on lipid metabolism. In particular we observed that mRNAs belonging 
to the fatty acids biosynthesis pathway genes ATP-Citrate Lyase (ACLY), Stearoyl-CoA 
Desaturase 1 (SCD1) and Elongation Of Very Long Chain Fatty Acids 6 (ELOVL6) 
were consistently downregulated upon DEPDC1A silencing suggesting a key role for 
this factor in controlling fatty acid metabolism in cancer cells. Indeed, ablation of 
 DEDPC1A caused a significant decrease of lipid droplets content and fatty acid 
desaturation in MDA-MB-231 cell line.  
ACLY, SCD1 and ELOVL6, as a part of fatty acids biosynthesis pathway, are specific 
targets of Sterol Regulatory Element Binding Protein (SREBP) transcription factors, 
master regulators of lipid metabolism. Interestingly, protein co-immunoprecipitation 
and Chromatin Immunoprecipitation assays demonstrated that DEPDC1A physically 
interacts with SREBP1 and that it is required for an efficient transcriptional activation 
of this particular subset of genes, thus acting as transcriptional cofactor of SREBP1.  
Finally, we showed that DEPDC1A, through SCD1 upregulation, is able to promote 
aggressive phenotypes, such as migration, and that DEPDC1A overexpression in 
normal cells is sufficient to induce sensitization toward SCD1 inhibition. 
 
This study unveils a novel oncogenic transcriptional program induced by the aberrant 
interaction between DEPDC1A and SREBP1 transcription factor that is able to induce 
fatty acid biosynthesis and desaturation in cancer cells and to establish a metabolic 
addiction that can be  potentially exploited in cancer therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 INTRODUCTION 
 
1.1 Breast cancer: current knowledge and challenges 
Among all cancer types, breast cancer figures as the most frequently diagnosed and the 
leading cause of cancer-related deaths among women worldwide (Torre et al., 2015). 
Breast cancer is considered a heterogeneous disease composed by several subtypes that 
differ at the level of molecular landscape, disease progression and response to therapy 
(Curtis et al., 2012). 
Currently, in clinical practice, diagnosis and treatment decisions are based on molecular 
classification that takes into account the hormone receptor status and grossly subdivides 
breast cancers into six major subtypes: luminal A, luminal B, Her2, claudin low, basal-
like breast cancer and normal-like (Perou et al. 2000; Prat et al. 2010). Although these 
molecular and clinico-pathological parameters can stratify breast cancers according to 
their aggressiveness and metastatic proclivity, in many cases they are not sufficient to 
predict their outcome and response to therapy. In fact, on one hand, several breast 
cancers are unresponsive to targeted- and chemotherapy and, on the other, a 
considerable proportion of patients develops metastatic breast cancer during therapy or 
experiences relapse (Mego et al., 2010). In both cases, this indicates that, despite 
advances in detection and therapy assignment, there are still molecular underpinnings 
that are not fully understood and that therapies tailored on the primary tumour are not 
effective in treating metastatic disease. The main limitation is that the therapeutic 
choices do not take into account the heterogeneity of the primary tumour. Moreover, 
little is known about the biological features of those cells that are able to metastasize or 
that remain dormant but still retain the ability to drive tumour recurrence (Mego et al., 
2010). For these reasons, it is becoming clear that current histopathological 
classification, although useful, has to be integrated with molecular data derived from 
dedicated research and genomic, transcriptomic and proteomic analyses of metastatic 
breast cancers in order gather molecular and phenotypic information to be translated 
into more personalized and precise treatment choices (Curtis et al., 2012; Norum and 
Sorlie, 2014). 
In this vein, recent studies indicate that metabolic reprogramming is crucial for the 
persistence of a small population of breast cancer cells that survives therapeutic 
intervention and that gives rise to tumour recurrence (Minimal Residual Disease). 
 Indeed, altered metabolic traits are observed to occur generally across many types of 
cancer cells. Environmental cues and cell intrinsic features of cancer cells have both 
shown to be at the basis of the metabolic reprogramming (Lyssiotis and Kimmelman, 
2017), which, in turn, is linked to drug resistance and relapse. The inhibition of 
metabolic pathways in vivo has been shown to decrease breast cancer reappearance and 
metastatic growth (Sounni et al., 2014; Havas et al., 2017; Pascual et al., 2017), 
indicating that hitting tumour metabolism can be a valid opportunity to target residual 
breast cancer and metastasis. 
 
1.2 Metabolic rewiring in cancer, an overview 
Metabolism is a complex network of multi-enzymatic pathways that work co-ordinately 
to: a) obtain energy through the degradation of complex molecules (nutrients) and b) 
transform simple molecules into cellular structural and functional components (e.g. 
membrane lipids, nucleotides, proteins etc.). - 
Tumour cells reprogram metabolic pathways to sustain their bio-energetic and 
biosynthetic needs according to both internal and external cues with a remarkable 
plasticity. This metabolic rewiring is instrumental for tumour formation and metastatic 
ability. In particular, altered metabolism, i.e. upregulated or suppressed conventional 
metabolic pathways upon tumorigenic mutations, sustains anabolic growth in nutrient-
replete environment and catabolic pathways are hijacked to support cell survival in 
adverse conditions (DeBerardinis and Chandel 2016). 
The first metabolic pathway that was shown to be altered, is glycolysis. It is known 
from early observations of the german scientist Otto von Warburg that quiescent and 
differentiated cells display a metabolism in which the glucose is fully degraded in CO2 
by glycolysis coupled to the Tri-Carboxylic-Acid Cycle (TCA). On the contrary, rapidly 
proliferating cells, like cancer cells, switch to aerobic glycolysis in which the glucose is 
fermented to lactate even when oxygen is present (Warburg effect) (Warburg et al., 
1925; Warburg, 1956) (Figure 1).  
 
  
Figure 1. The Warburg Effect. Differences between oxidative phosphorylation, anaerobic glycolysis, 
and aerobic glycolysis (Warburg effect). Non proliferating (differentiated) tissues metabolize glucose to 
pyruvate via glycolysis and then completely oxidize most of that pyruvate in the mitochondria to CO2. 
When oxygen is limiting, cells can ferment pyruvate in lactate (anaerobic glycolysis). In contrast, cancer 
cells tend to convert most glucose to lactate regardless of whether oxygen is present (aerobic glycolysis). 
This property is common to normal proliferative tissues. (Vander Heiden et al., 2009). 
 
The reasons why proliferating cells prefer metabolism with a lower energy yield (2 
versus 36 ATP for each glucose molecule) when the energy demand is the highest (such 
as during mitosis) puzzled the scientists for decades. 
The first hypothesis for this conundrum was that the mitochondria of cancer cells were 
not properly functioning, but this was disproved by the evidence that cancer cells do not 
have defects in oxidative metabolism (Frezza and Gottlieb, 2009); now it is clear that 
the reduced energy amount derived from aerobic glycolysis is compensated by an 
increased glucose absorption, which in many cases is sustained by the overexpression of 
the glucose transporters in cells membranes (GLUTs), and the overexpression of many 
glycolytic enzymes such as Hexokinase 1 and 2 (HKs), Glyceraldeyde-3-Phosphate-
Dehydrogenase (GAPDH) and Lactate Dehydrogenase (LDH) (Macheda et al., 2005; 
Marin-Hernandez et al., 2006). 
Moreover aerobic glycolysis provides proliferating cells with several advantages, such 
as a shorter and faster way to produce ATP and the production of intermediates for 
many biosynthetic pathways. Moreover it allows the cells to use the mitochondria as 
functional biosynthetic organelles rather than ATP factories (Ward and Thompson, 
2012), as for instance glycerol and citrate in the mitochondria are converted into lipids, 
oxaloacetate and pyruvate are used for the biosynthesis of non-essential amino acids, 
 ribose sugar for nucleotide biosynthesis, and finally the pentose phosphate pathway for 
NADPH production. Aerobic glycolysis furthermore eliminates the dependency of 
energy production from oxygen concentration, which, in the case of rapidly 
proliferating tumours, would be a limiting factor (Cairns et al., 2011). Finally, the lactic 
acid, which is massively produced as a waste of aerobic glycolysis, is secreted in the 
microenvironment, which becomes acidic, thus boosting tumour invasion. Lactate can 
also be taken up by adjacent stromal cells and used as an energy substrate to support 
growth or to generate and secrete pyruvate, which is then taken up by the cancer cells in 
a paracrine loop (Romero-Garcia et al., 2016). 
Since the seminal discovery of Warburg, many other observations have been made to 
confirm and extend the concept that proliferating cells have a different metabolism 
comparing to the quiescent ones, and that proliferating cancer cells display altered 
metabolic pathways (Figure 2). Indeed, alterations in lipid homeostasis have been 
shown to be required for tumour growth and progression. In particular, it has been 
demonstrated that cancer cells display an increased lipid uptake and, unlike non 
transformed cells, activate de novo lipid biosynthesis for the production of fatty acids 
and cholesterol (Santos and Schultze 2012; Luo et al., 2017); lipids are known to be 
required for biomass generation, signalling regulation and energy production and hence 
they are crucial for proliferating cells. Interestingly, recent findings revealed that cancer 
stem cells, although not rapidly proliferating, are addicted to specific lipid transporters 
and lipid modifications (Pascual et al., 2017; Li et al., 2017; Noto et al., 2017). 
 
 
 Figure 2. Signalling pathways regulating cancer metabolism. Schematic representation of the 
signalling pathways that regulate cancer metabolism. Alterations of the PI3K/Akt/mTOR, p53, MYC or 
HIF1 signalling pathways induce the Warburg effect, anabolic growth, and cancer progression 
(DeBerardinis and Chandel, 2016). 
 
Metabolic reprogramming discriminates cancer cells from the surrounding cells and 
from most other non-transformed cells in the body. Hence the major goal is to exploit 
this diversity to selectively eradicate the disease. Metabolic characterization of cancer 
cells will help in understanding those processes without which tumour growth and 
dissemination would be impaired; in particular, the enzymes that belong to those 
metabolic pathways can be potentially inhibited in order to deprive cancer cells of 
crucial metabolites without affecting normal tissues. In this line many efforts are 
ongoing in this field to inhibit the Warburg effect (targeting tumor specific glycolytic 
enzymes or glucose transporters) or the lipid biosynthetic pathway (Hay 2016; Roehrig 
and Schulze 2016). 
 
 
Figure 3. Targeting cancer metabolism. Schematic illustration of metabolic pathways that can be 
targeted in malignant cells. Blue boxes indicate enzymes and transporters that may be useful therapeutic 
targets in cancer. Green ovals represent transcription factors that alter metabolic pathways. (Teicher et al., 
2012). 
 
 1.2.1 Molecular underpinnings of breast cancer metabolic reprogramming. 
The molecular mechanisms that underlie metabolic shifts in cancer cells are complex 
and still understudied. Many breast cancers harbour activating mutations in genes like 
growth factor receptors (RTKs), G-proteins (RAS), and kinases (PI3K, AKT), or 
inactivating mutations in negative regulators of proliferation and metabolism like 
PTEN, TP53, VHL, RB. These genetic lesions cause the constitutive activation of 
growth factor signalling pathways that lead to aberrant cell proliferation and cancer-
associated metabolic reprogramming (Nik-Zainal et al., 2016). 
Hyper-activation of the PI3K/AKT/mTOR axis is one of the most frequent events in 
cancer (Hay 2016) and, alone, it can trigger the Warburg effect also in non-transformed 
cells (DeBerardinis et al., 2007). Indeed, in breast cancer it leads to i) an increased 
glucose uptake through the over-expression of glucose transporters (GLUT1-4) on cell 
membranes (Godoy et al., 2006; Garrido et al., 2013); ii) induction of glutamine uptake 
and catabolism; iii) fatty acids biosynthesis in breast cancer through the upregulation of 
ATP-Citrate Lyase (ACLY), Acetyl-CoA Carboxylase (ACC), and Fatty Acid Synthase 
(FASN) enzymes; iv) cholesterol biosynthesis through deregulation of downstream 
SREBP2 transcription factors (Freed-Pastor et al., 2012).  
To induce the metabolic reprogramming a broad change in gene expression is also 
required, which can be accomplished through the alteration of the activity of many 
transcription factors; in breast cancer, as in many other neoplasms, MYC, HIF1 and p53 
are central regulators of cell metabolism and their dysregulation is responsible for 
cancer associated metabolic rewiring (Teicher et al., 2012).  
MYC belongs to a family of transcription factors (c-MYC, L-MYC, s-MYC, and N-
MYC) and it is required for cell proliferation. In breast cancer MYC drives glucose 
metabolism by suppressing the expression of thioredoxin-interacting protein (TXNIP), a 
potent negative regulator of glucose uptake and glycolysis (Shen et al., 2015). 
Moreover, MYC activation is also able to rewire the glutamine metabolism through the 
activation of glutaminase 1 and 2, which are important enzymes in the glutaminolysis 
pathway and fundamental to produce anabolic substrates (i.e. for lipogenesis) (Shajahan 
et al., 2014). 
The c-MYC locus is frequently amplified in breast cancer and it can be activated as a 
downstream target of many oncogenic signalling pathways such as RAS-MAP-ERK 
cascade or mTOR complexes (Long et al., 2016).  Interestingly, a MYC-associated 
 signature has been linked with TNBC (Fallah et al., 2017), possibly reflecting its role in 
mediating breast cancer aggressiveness. 
HIF1 (Hypoxia inducible factor) is a transcription factor, which is activated by a variety 
of stress conditions like hypoxia, inflammation, and oxidative stress. It is controlled by 
the coordinate action of prolyl hydroxylases and the ubiquitin ligase and tumor 
suppressor Von Hippel-Lindau (VHL). Several studies link HIF1 activity to breast 
cancer aggressiveness; in particular, high HIF1 expression levels negatively correlate 
with patients’ survival and, more important, HIF1 was found overexpressed in 
circulating tumour cells of breast cancer patients and in breast cancer metastatic lesions 
(Gilkes and Semenza 2013). After its activation, HIF1 is able to induce the Warburg 
effect by upregulating GLUT1, HK1, HK2, and LDHA, as well as the lactate-extruding 
enzyme monocarboxylate transporter 4 (MCT4) (Pouyssegur et al., 2006; Semenza, 
2007). HIF1 is also able to dampen oxidative phosphorylation by inhibiting the 
conversion of pyruvate to acetyl-coA through pyruvate dehydrogenase (PDH). 
The importance of abnormal HIF1 activation in tumours relies in its ability to promote 
metabolic adaptation of the cell in response to the hostile cancer microenvironment.  
 
1.3 The role of TP53 in breast cancer and metabolism 
The discussion about the major players in the regulation of breast cancer metabolism 
wouldn’t be exhaustive without describing the tumor suppressor protein p53. p53 is a 
potent transcription factor, encoded by the TP53 gene, that plays a central role in 
cellular homeostasis and prevention of tumor growth. Indeed, p53 is activated by 
different cellular insults, that could threaten genomic stability, and triggers a complex 
and coordinated response that, depending on the inputs, can lead to cell cycle arrest, 
senescence or cell death, thus acting as onco-suppressor (Kaiser and Attardi, 2017). 
In normal conditions p53 protein is kept at low levels by its physiological degradation 
through the interaction with the ubiquitin ligases MDM2 and MDMX and the 
proteasome machinery. Under stress conditions (DNA damage, irradiation, hypoxia, 
nutrient starvation, activated proto-oncogenes), p53 is post-translationally modified and 
the interaction with MDM2/MDMX is inhibited, thus leading to the accumulation of the 
protein and activation of its functions (Bieging et al., 2014).  
As an onco-suppressor, p53 has an important impact also on cellular metabolism; p53 is 
able to dampen glycolysis by direct transcriptional repression of GLUT1 and GLUT4 
(Schwartzenberg-Bar-Yoseph et al., 2004), and the induction of TIGAR (TP53-induced 
 glycolysis and apoptosis regulator) a p53 target gene able to lower fructose-2,6-
bisphosphate levels in cells, thus inhibiting glicolysis (Bensaad et al., 2006). Moreover, 
p53 induces the expression of IGFBP3 and PTEN to negatively regulate AKT 
signalling, and induces the expression of AMPK-β and TSC2 by inhibiting mTOR 
(Feng and Levine, 2010). Simultaneously, wild type p53 is able to inhibit accumulation 
of lipids (Yahagi et al., 2003; Jang et al., 2011), to induce oxidative phosphorylation 
and maintain the mitochondrial mass and activity (Gottlieb and Vousden, 2010). In this 
way, p53 can oppose to the instauration of the Warburg effect and other metabolic 
signatures, which are associated with active proliferation and that, together with the loss 
of apoptosis induction and increased genomic instability, can ultimately lead to 
malignant transformation. 
Mutations in TP53 are the most frequent genetic lesions in cancer (Kandoth et al., 2013) 
with different rates across different cancers, ranging from 10% of all cases in 
hematopoietic malignancies to 90% in ovarian serous carcinomas (Rivlin et al., 2011). 
In addition, mutations in TP53 have been associated to poor prognosis in breast cancer 
patients and are among the most frequent mutations in metastatic breast cancers 
(Robinson et al., 2017). 
The majority of TP53 mutations (>70%) are missense mutations that most frequently hit 
the region encoding for the core DNA binding domain (Mantovani et al., 2017). There 
is enrichment in the specific residues R175, R248, R249, R273, R282, and G245, which 
are named hot-spot mutations (Brosh and Rotter, 2009) (Figure 4).  
Mutations can lead either to the complete abrogation of protein expression or to the 
expression of truncated or full length mutated proteins that abrogate the wild type (WT) 
functions of the transcription factor. Moreover, in the case of missense mutants, the 
mutated protein can exert a dominant negative (DN) effect on the remaining wild type 
allele (if the mutation is restricted to one allele), leaving the cells without a crucial 
checkpoint (Parrales and Iwakuma, 2015). 
 
c 
    
Figure 4. Missense mutations in TP53 locus and their effect on cancer  (a) Pie chart representing the 
different tumour-derived mutation types reported in the IARC TP53 Mutation Database. (b) The 
distribution of reported missense mutations along the aminoacid sequence of p53. The six most common 
hotspot mutations are highlighted in yellow for DNA-contact mutations, green for locally distorted 
mutants and blue for globally denatured mutants. (Brosh and Rotter, 2009). (c) Phenotypic effects of 
TP53 missense mutations (Brosh and Rotter, 2009). 
 
Hotspot mutations in p53 are traditionally classified in two groups: conformational 
mutants, in which the folding of the core domain of p53 is altered, thus impeding the 
p53 protein to bind the promoters of its target genes, and the DNA contact mutants, with 
those residues mutated that are responsible for directly binding DNA, but that still retain 
a near-native core domain structure (Figure 4) (Bullock et al. 2000; Cho et al. 1994; 
Joerger et al., 2008). In addition, mutant p53 is stabilized and activated in cancer cells in 
a context-dependent manner (Kim and Lozano, 2018). 
Beyond loosing WT properties and exerting DN activity, hotspot mutants are endowed 
with neomorphic features (Gain-of-function, GOF), which foster cancer growth and 
progression (Soussi and Wiman, 2015). In fact, although the protein has lost the ability 
to bind DNA, it can nevertheless impact on gene transcription by establishing aberrant 
interactions with other transcription factors diverting their physiological activity and 
eliciting oncogenic effects (Muller and Vousden, 2013). In cancer, the effects of mutant 
p53 GOF on cellular homeostasis are pervasive: it can directly inactivate p73/p63 
proteins, which are members of the p53 family with onco-suppressive functions 
partially overlapping with p53 and promote tumorigenesis (Strano et al., 2000; Strano et 
al., 2002; Adorno et al., 2009). In addition, it impacts on the chromatin structure 
fostering genomic instability and aneuploidy (Murphy et al., 2000; Jong et al., 2004; 
Polotskaia et al., 2015), it promotes cell survival exerting a negative effect on apoptosis 
 (Vegran et al., 2007; Lim et al., 2009), it increases cell proliferation by cell cycle genes 
transactivation (Di Agostino et al., 2006; Liu et al., 2001), it induces cell migration and 
invasion through integrins and Epidermal Growth Factor Receptor (EGFR) recycling 
(Muller et al., 2009) and it triggers neo-angiogenesis and inflammation (Fontemaggi et 
al., 2009; Weisz et al., 2007; Yeudall et al., 2012). Furthermore, work performed in our 
laboratory elucidated how mutant p53 increases breast cancer aggressiveness through 
induction of a specific transcriptional program (Girardini et al., 2011), and inhibition of 
various oncosuppressive pathways through the upregulation of the proteasome 
machinery (Walerych et al., 2016).  
From the viewpoint of metabolism, one of the most striking observations is that mutant 
p53 in breast cancer is able to actively bind to the SREBP2 transcription factor, 
inducing the expression of many genes in the mevalonate pathway, promoting 
cholesterol and isoprenoid synthesis in TNBC (Freed-Pastor et al., 2012). Building on 
this, our laboratory demonstrated that one of the major consequences of the aberrantly 
activated mevalonate pathway is the RhoA-dependent activation of YAP and TAZ 
(Sorrentino et al., 2014), two oncogenes, which are important regulators of organ 
growth and regeneration (Piccolo et al., 2014) and for BC metastasis (Kim et al., 2015). 
Moreover, mutant p53 induces the expression of genes involved in fatty acid synthesis, 
such as FASN (Freed-Pastor et al., 2012) and promotes glycolysis and the Warburg 
effect in breast cancer cell lines through the induction of glucose uptake and glycolytic 
flux (Zhang et al., 2013). Moreover recent evidence indicates that in addition to 
glycolysis, mutant p53 is able to induce oxidative phosphorylation in breast cancer cell 
lines, although there is no general consensus about the ability of all the mutants to 
induce these phenotypes to the same extent (Eriksson et al., 2017). Mutant p53 is also 
involved in promoting Insulin signalling and AKT1 activation by binding and 
inactivating the oncosuppressor DAB2IP (Valentino et al., 2017). 
A recent study shows that mutant p53 is also able to decrease AMPK activity; AMPK is 
a metabolic sensor and it is activated in energy deficiency conditions (Low ATP/high 
AMP); when activated, it phosphorylates a wide range of targets in order to maximize 
ATP production, through the increase of catabolic processes, and to downregulate 
anabolic pathways, thus inhibiting cell growth; in presence of mutant p53 proteins, the 
activation of AMPK in response to metabolic stress conditions (glucose deprivation, 
serum starvation) was reduced, indicating that mutant p53 is able to impair an important 
tumour suppressor metabolic checkpoint (Zhou et al., 2014). 
 1.4 The Sterol Regulatory Element Binding Proteins (SREBPs) and lipid 
metabolism. 
Lipid metabolism has been found connected in many ways to cancer progression and 
metastasis, thus, understanding how the control on lipid homeostasis is exerted, is of 
crucial importance. The master regulators of lipid metabolism are Sterol Regulatory 
Element Binding Proteins (SREBP), which are ER membrane embedded transcription 
factors responsible for the transcription of all the enzymes required for the lipid 
biosynthesis and scavenging (Brown and Goldstein, 1997; Hua et al., 1996; 
Radhakrishnan et al., 2004). 
SREBP proteins are mainly regulated by a negative feedback mechanism exerted by 
cholesterol. They are associated with SCAP (SREBP-Cleavage Activating Protein), a 
cholesterol sensing ER transmembrane protein; when cholesterol levels are high, SCAP 
interacts with INSIGs proteins (Insulin Induced Genes), which exerts an inhibitory 
control over SCAP/SREBPs complex by retaining it in the endoplasmic reticulum; 
when the levels of cholesterol are low, the SCAP/SREBPs complex detaches from 
INSIG allowing the transport of the complex to the Golgi apparatus via COPII 
vescicles. At the Golgi level two proteases (S1P and S2P) cleave SREBP into an active 
fragment (corresponding to the N-terminal of the protein) that migrates into the nucleus 
and activates the transcription of target genes. The transcriptional program activated by 
SREBPs in response to the low levels of cholesterol induces the biosynthesis and the 
uptake of this important metabolite in order to restore the physiological intracellular 
concentration (Figure 5) (Goldstein and Brown, 2006).  
 
  
Figure 5. Regulation of lipid metabolism by Sterol regulatory element binding proteins (SREBPs). 
Under conditions of copious sterol in the endoplasmic reticulum (ER), the ER retention protein INSIG 
prevents entry of the SREBP–SCAP (SREBP cleavage activating protein) complex to COPII-coated 
vesicles. Transport of SREBP to the Golgi is needed for proteolytic release of the transcription factor, 
which is then transported to the nucleus to activate sterol-regulated genes (Ikonen 2008). 
 
There are two genes encoding for two different SREBPs: SREBF1 and SREBF2 from 
which SREBP1 and SREBP2 proteins are generated. From SREBF1 two different 
isoforms are produced, SREBP1a and SREBP1c, using a different TSS (Ikonen, 2008). 
SREBP1 and SREBP2 have a different tissue distribution and a distinct but partially 
overlapping transcriptional program. While the former controls the fatty acids 
biosynthesis, the second is a master regulator of cholesterol metabolism. SREBP1a and 
SREBP1c have similar functions but a different expression pattern: SREBP1c is the 
predominant isoform in most tissues and it is activated by nutritional stimuli like insulin 
signalling (Shimomura et al., 1998), while SREBP1a expression is specific for intestinal 
epithelium, heart, bone marrow and dendritic cells (Im et al., 2011). 
 
1.4.1 Role of SREBP transcription factors in cancer 
Enhanced lipogenesis and lipid uptake have been observed in many rapidly proliferating 
cancer cells, and SREBPs, although never mutated, are found often overexpressed in 
cancer cells and several SREBPs activation mechanisms have been evidenced. For 
example, in glioblastoma, SCAP has been found to be glycosylated; this modification 
 diminishes its affinity for INSIG1 with consequent increased trafficking of 
SCAP/SREBPs complex to the Golgi (Cheng et al., 2015). 
In tumours with hyperactivated PI3K/Akt/mTOR pathway SREBPs are significantly 
more active and couple the enhanced glycolytic flux in cancer cells to lipogenesis and 
lipid uptake in order to meet the increasing lipid demand of rapidly proliferating cells. 
SREBPs have been found to be hijacked by mutant p53 to increase the mevalonate 
pathway and fatty acid biosynthesis genes, as described before (Freed-Pastor et al., 
2012). 
Although lipogenesis and SREBPs hyperactivity are crucial for cancer progression, 
these transcription factors do not seem to be promising therapeutic targets; indeed, even 
if inhibitors of SREBPs, such as fatostatin, are available, their effect on cancer 
progression might be counterproductive; inhibition of SREBPs increases Thyroid C Cell 
cancer aggressiveness and proliferation and, consistently, overexpression of SREBP1a 
causes G1 arrest by inducing cell cycle inhibitors (Nakakuki et al., 2007). Moreover, 
genetic ablation of both SREBPs causes apoptosis in untransformed cells (Griffiths et 
al., 2013).  
On the contrary, targeting downstream lipogenic enzymes might be a more appropriate 
and effective strategy. In particular, growing interest is directed on SCD1 (Stearoyl-
CoA Desaturase 1), an enzyme responsible for the mono-unsaturation of fatty acids. 
SCD1 generates oleic acid (C18:1) from stearic acid (C18:0) and has been found 
overexpressed in multiple cancers, in particular in hypoxic conditions. Genetic ablation 
or pharmacological inhibition cause cancer cell death and arrest cell migration (Fritz et 
al., 2010; Peck et al., 2016). Moreover, a recent paper showed that SCD1 inhibition 
causes the death of Cancer Stem Cells in lung and ovarian cancer (Noto et al., 2017; Li 
et al., 2017) and another work indicates that SCD1 is requested for stemness 
maintenance (Ben-David et al., 2013). 
Mono and poly-unsaturated fatty acids (MUFAs and PUFAs) are important for several 
biological processes: they regulate membrane fluidity and they are precursors of many 
signalling molecules such as lysophosphatidic acid. Moreover MUFAs and PUFAs are 
required for post-translational modifications of proteins, and, in this way, they regulate 
signalling pathways such as WNT (Rios-Esteves et al., 2013; Noto et al., 2017).  
In vitro studies reveal that SCD1 inhibition is deleterious only in absence of exogenous 
lipids, but in vivo experiments show that silencing of SCD1 reduces the growth of lung, 
prostate and liver cancers (Scaglia et al., 2008; Budhu et al., 2013; Fritz et al., 2010).  
 Also inhibition of Fatty Acid Elongase 6 (ELOVL6) has shown to reduce lung 
squamous cells carcinoma growth in vivo (Marien et al., 2016). Inhibition of SCD1 and 
ELOVL6 as a strategy to alter the quantity and the quality of the fatty acids, may 
therefore have a deep impact on cancer cell biology. 
 
1.5 DEPDC1A and the DEP Domain Containing Proteins 
A work published by our laboratory identified a mutant p53-driven transcriptional 
signature, associated with breast cancer aggressiveness and poor survival of BC patients 
(Girardini et al., 2011), that includes 10 genes, such as BUB1, C21ORF45, CENPA, 
CYCLIN E2, CPSF6, DEPDC1A, EPB41L4B, FAM64A, NCAPH and WDR67. 
In particular we focused our attention on DEPDC1A (DEP Domain Containing 1A), 
because, among all signature genes, it was the strongest inducer of tumour 
aggressiveness and invasion (Girardini et al., 2011) and because its tumorigenic activity 
was linked to important processes like inflammation (Harada et al., 2010). Importantly, 
DEPDC1A overexpression almost completely rescued  the  decrease of cell  migration 
associated with mutant p53 knock-down (Girardini et al., 2011), revealing that it 
promotes aggressive phenotypes also independently from mutant p53.  
Few reports are available about DEPDC1A functions in health and disease but, 
importantly, its overexpression has been associated with cancer progression. It has been 
reported as overexpressed in human bladder cancer tissues and cell lines, while its 
mRNA was not detected in normal adult tissues and cells, with the only exception of 
testis (Kanehira et al., 2007).  Other works showed that it is overexpressed also in breast 
cancer (Kretschmer et al., 2011), multiple myeloma (Kassambara et al., 2013), lung 
cancer (Okayama et al., 2012), prostate cancer (Huang et al., 2017) and nasopharyngeal 
carcinoma (Feng et al., 2017).  
Harada and colleagues have shown that DEPDC1A promotes tumorigenesis through the 
activation of the NF-kB pathway by the transcriptional repression of the A20 gene, a 
known inhibitor of NF-kB activity (Shembade et al., 2010); since DEPDC1A does not 
have any recognized DNA binding domain, the transcriptional repression is achieved 
through the interaction with the ZNF224 transcription factor, revealing for the first time 
a role for DEPDC1A as a transcriptional co-factor. Moreover, the treatment with a cell-
permeable dominant negative peptide (11R-DEP: 611-628) that interferes with the 
DEPDC1A-ZNF224 complex induces growth arrest and apoptosis in bladder cancer 
 cells, making this complex a promising therapeutic target for treatment in bladder 
cancer (Harada et al., 2010). 
An alternative role was suggested by Mi and colleagues, indicating DEPDC1A as a cell 
cycle regulator (Mi et al., 2015). They showed that DEPDC1A is strongly expressed 
during the mitotic phase in cancer cells and that its genetic ablation with short 
interfering RNAs leads to mitotic arrest and defects, while in another paper it is shown 
that the effect of DEPDC1A on mitosis is due to its localization on centrosomes (Chen 
et al., 2017). 
Although the functions of DEPDC1A both in physiological and neoplastic conditions 
are not fully understood, all these data point out an important role of DEPDC1A in 
tumorigenesis in a broad spectrum of cancers and suggest that its function is amenable 
for therapeutic interventions. In this perspective, different efforts have been made to 
synthetize immunogenic epitopes by us and by others, in order to generate DEPDC1A-
based anti-tumour vaccines (Obara et al., 2012; Tosi et al., 2017). 
  
The DEPDC1A gene is located on chromosome 1 and it encodes  two  main protein 
variants, annotated as DEPDC1A isoform 1 (DEPDC1A-V1: GeneBank Accession 
AB281187), consisting of 12 exons that encode an 811 amino-acid protein,  and  
DEPDC1A  isoform  2  (DEPDC1A-V2:  GeneBank  Accession  AB281274), consisting  
of  11  exons  that  encode  a  527  amino-acid  protein. These two splice-variants differ 
by a 284 amino acid sequence encoded by exon 8 present only in isoform 1 (Figure 6); 
it is not clear how the expression of these two isoforms is regulated, but our 
unpublished data indicate that the variant 1 is mainly expressed in cancer cell lines, 
while the variant 2 is expressed also in non-transformed cell lines. Both isoforms 
possess a Nuclear Localization Signal (NLS), and are nucleo-cytosolic proteins, in line 
with the roles of DEPDC1A in the regulation of the mitotic spindle and in 
transcriptional modulation (Kanehira et al., 2007).  
 
 
  
Figure 6. DEPDC1A isoforms and protein domain prediction. Upper panel: schematic representation 
of the human DEPDC1A gene organization, and the differences between the two variants. Bottom panel: 
DEPDC1A domain prediction in both isoforms. 
 
DEPDC1A is highly conserved among a wide range of species from C. elegans to 
humans. The nematode ortholog let-99 acts upstream to the heterotrimeric G protein 
alpha subunit GPA-11 to control the activation of JNK-1 and induce apoptosis after 
vincristine treatment (Sendoel et al., 2014). In humans there is a paralog named 
DEPDC1B, which acts as a mitosis promoting factor, coordinating de-adhesion events 
by RhoA inhibition, thus inducing the entry in M-phase (Marchesi et al., 2014). 
DEPDC1A belongs to the DEP domain containing family of proteins, which share in 
their N-terminus a conserved DEP domain, a motif of about 80-100 amino acids, named 
after the three proteins it was initially found in (Dishevelled, Egl-10, Pleckstrin) 
(Ponting et al., 1996; Karrath et al., 1998). Further analysis of the sequence of 
DEPDC1A reveals also two predicted RhoGAP (Rho GTPase Activating Protein) 
domains in V1 isoform and only one in V2.  
 
1.5.1 DEP domain 
The DEP Domain is a globular protein domain conserved among all the eukaryotes 
(Civera et al., 2005) and it is present, as a single copy or in tandem, in 64 human 
proteins (Ponting et al., 1996).  DEP domains display a unique alpha helix/beta sheet 
fold and have been implicated in membrane binding utilizing different mechanisms 
 (Ballon et al., 2006; Wong et al., 2000) and it is involved in signal transduction (Figure 
7). 
 
 
Figure 7. DEP domain structures. Cartoon structures of Dishevelled, EGL-10 and pleckstrin (DEP) 
domains that show their characteristic αβ fold. DEP domains comprise a conserved helical core, which 
consists of three helices and a protruding β-hairpin arm between the helices α1 and α2. This helical core is 
highly conserved in all DEP domains (Consonni et al., 2014). 
 
Multiple sequence alignments and using neighbour-joining phylogenetic trees allowed 
to identify 6 distinct subfamilies of the DEP domain containing proteins: i) Dishevelled 
(Dsh) subfamily, ii) RGS (Regulator of G protein Signalling) proteins, iii) Epac family 
(Exchange Protein directly Activated by cAMP), iv) Pleckstrin proteins, v) the FYVE 
containing kinases (proteins with the FYVE domain, from first letter of the first four 
proteins in which it was found Fab1p, YOTB, Vac1p and EEA1) and vi) yeast proteins 
with divergent DEP domains (Civera et al., 2005). 
For some of these proteins, the role of the DEP domain has been studied; in dishevelled 
protein, the DEP domain is important for the activation of c-Jun N-terminal kinase 
(JNK), the upregulation of Beta-catenin activity, and the stimulation of Lef-1 mediated 
transcription (Warton et al., 2003; Boutros et al., 1998). Moreover the DEP domain of a 
photoreceptor-specific signalling protein, RGS9 (Regulator of G protein Signalling 9), 
plays an essential role in its own intracellular delivery interacting with R9AP, a member 
of the extended SNARE protein family (Martemyanov et al., 2003). 
In Pleckstrin proteins the DEP domain represents a novel and distinct subfamily and 
shares important structural features with the DEP domains of Dishevelled. Interestingly, 
the Pleckstrin DEP domain does not seem to be directly involved in membrane 
localization of the protein, and its molecular function remains unknown (Civera et al., 
2005).  
 In Epac2, the DEP domain is crucial for membrane localization. Epac is a target of 
cyclic AMP, an important second messenger in signal transduction and functions as a 
guanine nucleotide exchange factor for the Ras-like small GTPase Rap (De Rooij et al., 
2000; Qiao et al., 2002).  
 
1.5.2 The RhoGAP domain 
The GAP domain mediates GTP hydrolysis in GDP in Rho GTPase proteins (22 
members in mammals (Ridley 2006) enhancing their GTPase activity, thus inducing the 
inactive state of the Rho proteins. 
The small GTPase proteins are members of the Ras superfamily and contain over 150 
members, divided into five major branches on the basis of sequence and functional 
similarities, named Ras, Rho, Rab, Ran and Arf  (Wennenberg et al., 2005). They share 
a ~20 kDa core G domain (corresponding to Ras residues 4–166) involved in GTP 
binding and hydrolysis (Vigil et al., 2010). In addition to the GAP proteins, the GTPase 
activity is modulated also by GEFs (Guanine nucleotide Exchange Factors), which 
activate GTPases by promoting the GTP-bound state, and GDIs (Guanine nucleotide 
Dissociation Inhibitors), which sequester the GTPases in their GDP-bound state (Figure 
8). 
 
 
Figure 8. The GDP-GTP cycle of G proteins. Ras superfamily proteins possess intrinsic guanine 
nucleotide exchange and GTP hydrolysis activities. However, these activities are too low to allow 
efficient and rapid cycling between their active GTP-bound and inactive GDP-bound states. GEFs and 
GAPs accelerate and regulate these intrinsic activities (Vigil et al., 2010). 
  
With the relevant exception of RAS, GTPase proteins are not commonly mutated in 
cancer, but deregulated expression or protein function of GEFs and GAPs have been 
found to have a role in tumorigenesis (Vigil et al., 2010).  
In regulating small RhoGTPases, the RhoGAP activity works as molecular switch, 
coupling extracellular inputs to intracellular signal transduction pathways. The RhoGAP 
domain is a motif of approximately 190 amino acids shared by ~70 proteins, which 
presents a conserved arginine residue termed the “arginine finger” which is essential for 
the catalytic activity (Amin et al., 2016). 
A structural study reveals that DEPDC1A Rho-GAP domain is probably not functioning 
because it lacks the arginine finger residue in position 242 which, as above-mentioned, 
is crucial for its activity (Amin et al., 2016). For this reason its role remains unclear. 
Nevertheless, RhoGAP proteins may play a role in biological processes independently 
from their RhoGAP activity; for example, α1-chimaerin, a RhoGAP protein lacking of a 
GAP activity, is able to bind GTPases such as Rac1 and Cdc42 and in this way 
cooperates within actin cytoskeleton remodelling processes (Kozma et al., 1996). 
Interestingly, also DEPDC1B possesses an inactive RhoGAP domain, but still is able to 
bind and inhibit RhoA (Marchesi et al., 2014). These observations therefore suggest a 
possible non-canonical role also for the RhoGAP domain of DEPDC1A.  
 
1.5.3 DEPDC1A as promoter of aggressive phenotypes in breast cancer. 
Unpublished work from our laboratory reveals that DEPDC1A is involved in multiple 
steps of breast cancer progression. Moreover, bioinformatic analysis reveals that 
DEPDC1A expression is significantly higher in breast cancers compared to normal 
tissues and that high DEPDC1A expression levels positively correlate with a poor 
prognosis in breast cancer patients. 
Importantly, the relevance of DEPDC1A in tumour progression and metastasis 
formation in vivo has been confirmed in a mouse mammary xenograft model, where 
cells depleted of DEPDC1A are not able to form primary tumours and metastases in 
immunocompromised mice.  
Interestingly, in vitro experiments showed that of the two isoforms, only the V1 seems 
to positively correlate with tumorigenesis, since its expression is detectable only in 
cancer cell lines while the V2 seems to have a broader spectrum of expression. 
Moreover, only  overexpression of the DEPDC1A-V1 isoform is able to induce 
 proliferation, migration, anchorage-independent growth, change in cell polarity and 
stemness features in a normal mammary epithelial cell line MCF-10A, while the V2 
only weakly induces some of these traits when overexpressed in these cells.  
All these results together suggest a robust oncogenic potential of DEPDC1A-V1, as also 
observed by others, which is able to induce tumour-like features in non-transformed 
cells and is required for tumour growth and metastasis formation in vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 AIM OF THE THESIS 
 
Metastatic breast cancer is usually an incurable disease. Modern therapeutic 
interventions have only palliative effects and are not able to avoid dissemination and 
cancer progression. The reasons of this failure have been mainly ascribed to tumour 
plasticity and heterogeneity, which still remain underestimated and, consequently, make 
it difficult to correctly stratify the patients according to outcome and metastatic risk. 
Moreover, such variability limits the effectiveness of therapeutic regimens, mainly 
based on the diagnosis of the primary tumour and which are not able to hit 
aggressive/metastatic tumour cells.  
It is becoming clear that the current methods of breast cancer diagnosis and 
classification, although useful, are not sufficient to embrace this growing complexity, 
thus making it necessary to integrate this knowledge with information derived from 
genetic, transcriptomic, epigenomic and metabolomic analyses of both primary tumours 
and disseminated cells, in order to find tumour dependencies that could be exploited to 
the specific detriment of metastatic cancer cells. 
In this perspective, work performed in our laboratory evidenced that DEPDC1A, a 
mutant p53 target gene, is a strong inducer of breast cancer progression in vitro and its 
abrogation strongly impairs metastasis formation in vivo. Moreover, data from literature 
evidenced that DEPDC1A is found overexpressed in many other tumours and associated 
to poor prognosis in patients, indicating that it might have a role in a broad spectrum of 
aggressive cancers. The fact that DEPDC1A is barely detected in normal cells and 
becomes overexpressed only in cancer further justifies the interest in this protein - and 
its molecular network - as potential therapeutic targets. 
Starting from these premises, we hypothesized that DEPDC1A could be relevant for 
metastasis formation and, therefore, the aim of this thesis was to: 1) understand, by 
using high-throughput transcriptomic analysis, the biological pathways that are 
deregulated in breast cancer through DEPDC1A and that could be relevant for cancer 
cell aggressiveness, 2) elucidate the molecular mechanisms by which DEPDC1A 
induces its oncogenic program, 3) find potential vulnerabilities that could be 
pharmacologically targeted.  
 
 RESULTS 
 
2.1 DEPDC1A transcriptionally regulates genes of the fatty acid biosynthesis 
DEPDC1A is poorly detectable in non-transformed cells, while it was shown to be 
overexpressed in many cancers from different tissue origin, and mainly associated to 
poor patients’ outcome (Kanehira et al., 2007). In addition, our previous unpublished 
results have unveiled that overexpression of DEPDC1A in a non-transformed breast cell 
line is able to induce malignant phenotypes, such as proliferation, migration, loss of cell 
polarity. Since the cellular functions of DEPDC1A are still poorly defined, we asked 
how DEPDC1A might impact on cancer cells’ biology. Based on its role as a 
transcriptional co-factor of ZNF224 and E2F1 (Harada et al., 2010; Huang et al., 2017), 
we performed a high-throughput transcriptomic analysis by RNA-seq of the highly 
metastatic MDA-MB-231 TNBC cells upon DEPDC1A silencing in order to gain novel 
insights into DEPDC1A functions. 
 
 
Figure 9. RNAseq analysis of total UP and DOWN regulated gene upon DEPDC1A silencing. Heat 
map representing the clustering of up-regulated and down-regulated genes upon control or DEPDC1A 
RNA interference, as indicated. Three samples for control and four for DEPDC1A silencing were 
analysed. 
 
 Compared to control silencing, 1362 genes were differentially expressed in DEPDC1A 
siRNA treated samples in a statistically significant manner by applying a cut off of 
logFC 0.75 and a p-value < 0.05. An unbiased analysis of functional annotation (AFA) 
of genes with significantly changed expression levels (by >0.5-fold) performed with the 
Ingenuity Pathway Analysis (IPA) software revealed that a great number of important 
biological processes were perturbed by DEPDC1A silencing. We chose to consider only 
those processes that were robustly downregulated according to their negative z-score. 
 
 
 
Figure 10. IPA Functional Annotation of DEPDC1A-modulated genes. Ingenuity pathway analysis of 
the genes with greater than 1.5 fold change in expression of MDA-MB-231 cells upon silencing of 
DEPDC1A with respect to control silenced cells. 
 
In line with previous publications and our data, the biological functions of 
inflammation, cell cycle, cell growth, proliferation and cellular movement appeared 
significantly enriched and downregulated. Notably, also lipid metabolism was 
significantly downregulated and represented an interesting novelty. In particular, we 
observed that several mRNAs all belonging to fatty acid biosynthesis pathway genes 
like ATP-Citrate Lyase (ACLY), Stearoyl-CoA Desaturase 1 (SCD1) and Elongation Of 
Very Long Chain Fatty Acids 6 (ELOVL6) were consistently downregulated, suggesting 
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 a role for DEPDC1A in controlling fatty acid metabolism in cancer cells. The 
downregulation of these enzymes was validated by qRT-PCR in MDA-MB-231 cells by 
using two independent siRNAs against DEPDC1A (Fig. 11). 
 
Figure 11. Validation of RNAseq results. (a): qRT-PCR validation of selected DEPDC1A induced 
genes. Changes in gene expression are indicated as fold change upon depletion by two independent 
DEPDC1A targeting siRNAs in MDA-MB-231 cells, relative to cells transfected with control siRNA. 
Error bars indicate s.d of at least 3 replicates, asterisk indicates p-value <0.05. (b) Western blot analysis 
of the cellular lysates of the experiments in (a). DEPDC1A protein isoforms V1 and V2 upon control and 
DEPDC1A (I) or (II) silencing are indicated; Actin levels are shown as a loading control. 
 
This result demonstrated that DEPDC1A positively regulates the expression of these 
genes in MDA-MB-231 breast cancer cell line. To corroborate our findings we 
performed an immunohistochemical analysis for SCD1 and DEPDC1A-V1 proteins in 
serial sections of a panel of human breast cancer biopsies. Here we show 
immunohistochemical staining of representative samples, where positive DEPDC1A-V1 
sample shows also high SCD1 protein levels, while DEPDC1A-V1 negative sample is 
negative also for SCD1; a statistical analysis performed taking into account all the 
examined samples shows a significant correlation between the two proteins (pvalue = 
0.0083) (Figure 12) . 
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DEPDC1A-V1 SCD1 SAMPLES 
+ + 4 
- - 10 
- + 3 
TOT  17 
P value = 0.0083 (Barnard unconditional test for superiority) 
 
Figure 12. Immunohistochemical staining for DEPDC1A-V1 and SCD1 in human breast cancer 
biopsies. (a): immunohistochemical staining for DEPDC1A-V1 and SCD1 in serial sections of 17 human 
breast cancer biopsies (representative samples are shown). (b): table showing the Immunohistochemical 
staining patterns of DEPDC1A-V1 and SCD1 in the breast cancer samples analysed.  
 
Considering that the number of these samples was limited, and therefore not sufficient 
to strongly corroborate the data, we wanted extend our analysis by interrogating the 
Breast Invasive Carcinoma gene expression dataset of TCGA 
(https://cancergenome.nih.gov/) which contains RNA-seq data relative to 1100 Breast 
cancer samples. We analysed the mRNA levels of ACLY, SCD1 and ELOVL6 in the 
a 
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 samples with high levels of DEPDC1A and, although it was not possible to find a strong 
correlation (Pearson Score <0.3), a positive trend was evidenced (data not shown).  
 
These data all together indicates that DEPDC1A regulates expression levels of fatty acid 
biosynthesis in breast cancer and let us hypothesize that overexpression of DEPDC1A 
in cancer cells could impact on de novo fatty acid biosynthesis and prompted us to 
investigate this possibility.  
Fatty acids biosynthesis is a multistep process that entails the condensation of Acetyl-
CoA molecules and NADPH consumption to produce straight carbon chains of different 
length. The pathway starts with a molecule of acetyl-CoA, that in mammals is produced 
mostly by carbohydrate metabolism, derived from pyruvate by pyruvate dehydrogenase 
(PDH) in the mitochondrion, which cannot be exported to the cytoplasm where the fatty 
acid biosynthesis occurs; therefore a molecule of citrate is diverted from the TCA cycle 
and translocated in the cytosol, where it is used by ACLY to produce acetyl-CoA and 
oxaloacetate, accomplishing the first lipogenic step; the TCA is not the only source of 
citrate, which can be retrieved also from glutaminolysis; ACLY is thus the enzyme that 
connects the carbohydrate and amino acid metabolism to the lipid biosynthesis pathway. 
To synthetize the fatty acid carbon chain, the acetyl-CoA is transformed in malonyl-
CoA by acetyl-CoA carboxylase (ACC) and then, by the activity of FASN, other acetyl-
CoAs are added until a 16 carbon atoms long fatty acid is obtained (palmitic acid). At 
this point the fatty acid molecule can be elongated, through elongase enzymes, like 
ELOVL6, and desaturated, through desaturases, such as SCD1, to obtain a pool of 
different fatty acids. 
Free fatty acids are extremely toxic for the cell, and, once they are synthetized, they are 
immediately incorporated in other molecules or employed in several processes, among 
which there are beta-oxidation, phospholipids formation and signal transduction; fatty 
acids can also be stored as triglycerides in lipid droplets. 
Lipid droplets (LDs) are subcellular organelles of neutral lipids storage (triglycerides 
and cholesterol esters) surrounded by a phospholipid monolayer. LDs are more than 
simple lipids repositories, in fact they participate in the maintenance of lipid 
homeostasis, they avoid lipo-toxicity, and they serve as an important buffer for 
oxidative stress (Walther and Farese, 2012). LDs are indicators of fatty acids and 
triglycerides biosynthesis and uptake; normally, apart from liver, adipose tissue and 
breast during lactation, cells do not form many droplets, but transformed cells have been 
 found to produce them in large quantity, probably due to an excessive lipid biosynthesis 
and uptake that would otherwise be toxic; in this way they were described to have an 
active role in promoting cell survival and tumorigenesis (Bozza and Viola, 2010).  
 
2.2 DEPDC1A induces lipid droplets formation and fatty acid desaturation. 
To understand if DEPDC1A is able to influence fatty acid synthesis we decided to 
measure the content of lipid droplets in MDA-MB-231 cells upon DEPDC1A silencing 
as a read out of lipid accumulation.  
First, to stain lipid droplets we employed a lipophilic fluorescent dye, named LD540, 
specific for neutral lipids (Spandl et al., 2009); then, in order to measure only the lipid 
biosynthesis process and avoid the contribution of lipid uptake, we measured the lipid 
droplets in cells grown in media supplemented with lipid free serum. As shown in 
Figure 13, upon treatment of MDA-MB-231 cells with two independent siRNAs for 
DEPDC1A, the content of lipid droplets was significantly reduced with respect to 
control silenced cells, suggesting that that DEPDC1A is able to impinge on both lipid 
synthesis and accumulation. 
 
Figure 13. Lipid Droplets staining in DEPDC1A depleted MDA-MB-231 cells. Images of lipid 
droplets stained with LD540 fluorescent dye in control (siCTRL) or DEPDC1A (I) and (II) siRNA 
(siDEPDC1A (I) and (II)) transfected MDA-MB-231 cells. Nuclei are stained with DAPI. The scale bar is 
20um. 
 
To confirm and extend the observation that DEPDC1A influences the lipid droplets 
content and to quantify the phenomenon, we knocked down DEPDC1A in different 
breast cell lines and measured fluorescently labelled lipid droplets by FACS analysis 
(Fig. 14). Intriguingly, while in the breast cancer cell lines MDA-MB-231, MDA-MB-
 468 and MCF-7 the fluorescence intensity was significantly reduced following 
DEPDC1A silencing, in normal mammary epithelium cells (MCF-10A), which have 
undetectable levels of DEPDC1A-V1, we did not observe any difference, thus 
confirming the specificity of our findings. 
 
 
Figure 14. FACS based quantification of lipid droplets following DEPDC1A depletion in a panel of 
breast cell lines. Quantification by FACS analysis of fluorescently-labeled lipid droplets in different 
breast cancer (MDA-MB-231, MDA-MB-468, MCF-7) and normal (MCF-10A) cell lines upon control or 
two independent DEPDC1A siRNAs. The levels of lipid droplets are expressed as fold change with 
respect to the control siRNA. Error bars indicate s.d of at least three replicates, asterisks indicate p-values 
<0.05.  
 
To formally demonstrate that the modulation of lipid droplets was DEPDC1A 
dependent, we generated stable MDA-MB-231 clones in which endogenous DEPDC1A 
was constitutively knocked down by a short hairpin RNA and an exogenous shRNA-
resistant DEPDC1A-V1 cDNA was stably overexpressed. Notably, as shown in Figure 
15, re-overexpression of DEPDC1A-V1 was sufficient to rescue the reduction of lipid 
droplets displayed in shDEPDC1A expressing cells, thus confirming our hypothesis.  
 
  
 
Figure 15. Overexpression of a siRNA resistant DEPDC1A in MDA-MB-231 depleted of the 
endogenous protein rescues lipid droplet formation. Images of lipid droplets stained with LD540 
fluorescent dye in MDA-MB-231 stably transduced with shControl, shDEPDC1A and with re-
overexpression of a shRNA-resistant DEPDC1A-V1 isoform. Nuclei are stained with DAPI. The scale 
bar is 20um. (b) Western blot analysis of the cellular lysates of the experiments in (a). DEPDC1A protein 
isoform V1 of cells transduced with CTRL or DEPDC1A short hairpin RNA and with an shRNA-
resistant DEPDC1A re-overexpression is indicated; Actin levels are shown as a loading control. 
 
Next, to understand if the effect exerted by DEPDC1A-V1 on lipid droplets 
accumulation was dependent on induction of its target genes, we employed MCF-10A 
cells stably overexpressing HA-tagged DEPDC1A-V1 and analysed their lipid droplets 
content by FACS. We were are able to observe an increased content of lipid droplets in 
DEPDC1A overexpressing cells (Figure 16a) and also increased SCD1 protein levels 
(Figure 16b), compared to the empty vector infected cells; in these same conditions we 
silenced SCD1 and we obtained a strong reduction of the phenotype (Figure 16a), 
indicating that the lipid-related transcriptional program activated by DEPDC1A is 
instrumental for the increased content of lipid droplets. 
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Figure 16. FACS based quantification of lipid droplets in MCF-10A cells following modulation of 
genes of the DEPDC1A/lipid axis. Quantification by FACS analysis of fluorescently-labeled lipid 
droplets in MCF-10A cells stably transduced with EMPTY or HA-tagged DEPDC1A-V1 vector upon 
control or SCD1 silencing. The levels of lipid droplets are expressed as fold change with respect to the 
EMPTY vector siCTRL. Error bars indicate s.d of at least three replicates, asterisks indicate p-value 
<0.05. (b) Western blot analysis of the cellular lysates of the experiments in (a). HA tagged DEPDC1A-
V1 and SCD1 proteins isoforms of MCF-10A cells transduced with EMPTY or DEPDC1A-V1 
overexpressing vectors upon CTRL or SCD1 silencing are indicated; HSP90 levels are shown as a 
loading control. 
 
To implement our findings in an in vivo setting, we took advantage of primary tumour 
samples derived from a mammary xenograft experiment of shCTRL or shDEPDC1A 
MDA-MB-231 cells. Since it was not possible to directly stain lipid droplets on those 
samples, we decided to verify the levels of specific markers of lipid droplets biogenesis, 
by controlling perilipin 2 (PLIN2) protein levels. PLIN2, is an ubiquitously expressed 
protein associated with LDs, which is crucial for both their formation and maintenance. 
Indeed, absence of PLIN2 has been shown to impair LDs formation (Sztalryd and 
Kimmel, 2014). As shown in Figure 17, in the shDEPDC1A samples we observed a 
strong reduction of SCD1 protein levels and, in parallel, a complete abrogation of 
PLIN2 protein expression, thus indicating a very likely reduction of LDs content. 
Moreover, this result indicates that also in vivo, DEPDC1A might be able to impinge on 
fatty acid metabolism by enhancing both fatty acid biosynthesis and LDs formation. 
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Figure 17. DEPDC1A silencing impairs fatty acid metabolism in vivo. (a) Scheme of the xenograft 
experiments with metastatic MDA-MB-231 cells, stably  transduced  with  a  lentiviral  vector  encoding  
for  the  firefly luciferase reporter gene and co-transduced with specific short hairpin RNAs targeting 
DEPDC1A or mock lentiviral vector, which were injected into mammary fat pad of nude mice. Tumour 
and lung metastatic growth were followed by caliper and bioluminescence measurements, respectively. 
After 31 days Control mice  (shCtrl) had outgrown tumours and metatases, while shDEPDC1A mice had 
reduced tumour growth and only limited metastasis. Tumours for both shCTRL and shDEPDC1A were 
extracted when they had reached the same dimension, lysed and used for western blot analysis. (b) 
Western blot of DEPDC1A, SCD1 and PLIN2 in frozen primary tumours samples derived from mouse 
mammary xenograft experiment shown in (a); Actin levels are shown as loading control. 
 
Apart from lipid accumulation, we next asked if, through SCD1 regulation, DEPDC1A 
was able to modify also desaturation levels of the fatty acids. To do so, we took 
advantage of gas chromatography/mass spectrometry analysis of Fatty Acid Methyl 
Esters (FAME) obtained through the saponification of lipids. This technique allows 
discriminating different fatty acids and their desaturation status. As shown in Figure 18, 
DEPDC1A-silenced MDA-MB-231 displayed a slight, nevertheless significant, 
a 
b 
 reduction of the of unsaturated fatty acid pool, with an effect comparable to that exerted 
by SCD1 silencing. 
 
Figure 18. Impact of DEPDC1A silencing on fatty acid saturation in MDA-MB-231 cells. (a) 
Quantification by FAME-LC/MS of the total saturated and unsaturated fatty acids in MDA-MB-231 cells 
upon DEPDC1A and SCD1 silencing; the values are expressed as relative percentage of the total fatty 
acid content. Error bars indicate s.d of 3 replicates, asterisk indicates p-value <0.05. (b) Western blot 
analysis of the cellular lysates of the experiments in (a). V1 and V2 isoforms of DEPDC1A protein and 
SCD1 of cells transfected with CTRL, DEPDC1A (I) and SCD1 siRNAs are indicated; HSP90 levels are 
shown as a loading control. 
 
All together these data show that DEPDC1A is able to increase fatty acids accumulation 
and desaturation, with an important effect on cancer associated lipid metabolism 
rewiring, thus offering a possible mechanism for DEPDC1A-induced cancer associated 
phenotypes. 
 
2.3 SCD1 inhibition impairs cell migration and viability. 
Our previous published and unpublished data indicate that DEPDC1A-V1 is able to 
induce many oncogenic phenotypes in non-transformed MCF-10A cells. In particular, 
we have shown that DEPDC1A is a strong promoter of migration and invasiveness. In 
order to understand if the lipid biosynthesis and unsaturation are instrumental for 
DEPDC1A-V1 activity, we took advantage of MCF-10A cells stably transduced with 
EMPTY- or HA-tagged DEPDC1A-V1 overexpressing vectors and we measured their 
migratory ability in a trans-well assay upon control- or SCD1 silencing. In line with our 
a b 
 results, DEPDC1A-V1 overexpression strongly induced cell migration, but, as 
evidenced in Figure 19, SCD1 silencing strongly impaired this phenotype, indicating 
that SCD1 activity is crucial for DEPDC1A-V1 induced migration. 
 
Figure 19. SCD1 silencing impairs DEPDC1A-V1 induced migration in MCF-10A cells. Migration of 
MCF-10A cells stably transduced with EMPTY- or HA-tagged DEPDC1A-V1 overexpressing vector 
upon control (siCTRL) or SCD1 silencing (siSCD1) by transwelling assays. The number of migrated cells 
is expressed as fold change with respect to the EMPTY vector siCTRL treated cells. Error bars indicate 
s.d of at least three replicates. Asterisks indicate p-value <0.05.  
 
 
Considering that cancer cells become dependent to oncogene-induced metabolic 
rewiring and that DEPDC1A may indeed contribute to it, we asked whether DEPDC1A 
overexpressing cells might be sensitive to SCD1 inhibition. To this aim we measured 
cell viability of EMPTY-vector or DEPDC1A overexpressing MCF-10A cells left 
untreated or treated with DMSO or the selective SCD1 inhibitor MF-438. As shown in 
Figure 20, while EMPTY MCF-10A cells were not affected by MF-438 treatment, the 
viability of DEPDC1A-V1overexpressing cells was significantly lower, showing that 
DEPDC1A-V1 overexpression is sufficient to induce a sensitization toward this 
metabolic inhibitor.   
  
Figure 20. DEPDC1A overexpression induces sensitization toward SCD1 inhibition in MCF-10A 
cells. ATP-lite assays were performed in MCF-10A cells stably transduced with EMPTY or DEPDC1A 
overexpressing vector left untreated (NT) or treated with DMSO or the SCD1 specific inhibitor MF-438 
(2uM).  Cell viability was measured with a multi-plate reader after 48h. The values are expressed in fold 
change with respect to the NT cells. Error bars indicate s.d of at least three replicates. Asterisk indicates 
p-value <0.05.  
 
2.4 DEPDC1A is a transcriptional cofactor of SREBP1. 
Based on DEPDC1A acting as a transcriptional co-factor, we next asked if the 
transcriptional regulation of the fatty acid biosynthesis genes was exerted at the level of 
their promoters. We chose to analyse the promoter of endogenous SCD1, as this was the 
most effectively regulated gene by DEPDC1A, and we performed a Chromatin 
Immunoprecipitation (ChIP) assay using an anti-DEPDC1A antibody or non-related 
IgGs as a negative control (Figure 21a). Three different regions of the SCD1 promoter 
and one in the first intron were analysed by qRT-PCR on the immunoprecipitated 
chromatin, (Fig. 21b) to determine the binding enrichment of DEPDC1A.  
 
  
Figure 21. DEPDC1A binds to the endogenous SCD1 promoter. ChIP assay of DEPDC1A or IgG 
antibodies on endogenous SCD1 promoter in MDA-MB-231 cells; three different regions of the SCD1 
promoter and the first intron were analysed by qRT-PCR; the enrichment of immunoprecipitated 
chromatin is expressed as fold change relative to the negative control IgG. Error bars indicate s.d of at 
least three replicates. Asterisk indicates p-value<0.05. (b) scheme representing the human SCD1 promoter 
with the analysed regions represented with respect to the transcription start site (+1). Enlargement of 
region C indicates presence of different TF response elements as indicated by diamonds, circles, triangles, 
and in particular a SRE element (black square). 
 
Interestingly, we observed a two-fold binding enrichment in region C, corresponding to 
a fragment located -251/-54 nucleotides upstream of the TSS (+1) (Figure 21a). This 
region has been reported to contain a poly-unsaturated fatty acid response element 
(PUFA), a binding region for the liver-x-receptor (LXR) transcription factor and a 
consensus sequence for SREBPs (Benè et al., 2001). This result together with the notion 
that SREBPs are master regulators of lipid metabolism and known regulators of ACLY, 
SCD1 and ELOVL6, prompted us to determine if DEPDC1A could exert its 
transcriptional activity through interaction with SREBPs. To this aim, we first 
demonstrated with co-immunoprecipitation assays that these proteins interact with each 
other, in particular we saw that the endogenous DEPDC1A protein interacts with the 
125 kDa full length form of SREBP1 in MDA-MB-231 cells (Figure 22).  
a 
b 
  
 
 
Figure 22. DEPDC1A interacts with SREBP1 transcription factor. Co-immunoprecipitation assay 
between endogenous DEPDC1A and SREBP1 in MDA-MB-231. 
 
Furthermore, to understand which SREBP1 isoform was involved and if DEPDC1A 
could bind also SREBP2, we overexpressed separately in HEK293T cells the nuclear 
and active form of SREBP1a, SREBP1c and SREBP2 proteins with an N-terminal flag 
epitope together with an HA-tagged DEPDC1A-V1. Co-immunoprecipitation 
experiments allowed us to observe that DEPDC1A is able to bind SREBP1a and to a 
lesser extent also SREBP2, but not to SREBP1c (Figure 23). 
 
 
 
Figure 23. DEPDC1A interacts with SREBP1a and SREBP2. Co-immunoprecipitation assays between 
DEPDC1A and the nuclear form of SREBP1a, SREBP1c and SREBP2 proteins overexpressed in 
HEK293T cells. 
 
To formally demonstrate that DEPDC1A is recruited to chromatin by SREBP1, we 
performed a ChIP assay using an anti-HA antibody or non-related antibody (IgG) in 
MDA-MB-231 cells overexpressing HA-tagged DEPDC1A-V1, upon Control or 
SREBP1 silencing. Region C of the SCD1 promoter, in which we previously observed 
DEPDC1A binding, was analysed by qRT-PCR and the result showed that, without 
 SREBP1, region C is not any more enriched in the chromatin immunoprecipitated by 
the anti-HA antibody (Figure 24), indicating that the ability of DEPDC1A to bind to the 
SCD1 promoter is lost in absence of SREBP1.  
 
 
Figure 24. DEPDC1A binds to the human SCD1 promoter through SREBP1. ChIP assay of 
DEPDC1A-V1 HA or IgG antibodies on endogenous SCD1 promoter in MDA-MB-231 cells upon 
control (siCtrl) or SREBP1 (siSREBP) silencing; region C was analysed by qRT-PCR and the enrichment 
of immunoprecipitated chromatin is expressed as fold change with respect to the negative control IgG. 
Error bars indicate s.d of at least three replicates. Asterisk indicates p-value<0.05. 
 
Next we asked whether the DEPDC1A-SREBP1 interaction is functional for the 
transcriptional activity of SREBP1. To this aim, we measured the binding ability of 
SREBP1 on the SCD1 promoter in cells with or without DEPDC1A siRNA by ChIP 
experiments. As shown in Figure 24, DEPDC1A depletion had a little effect on 
SREBP1 chromatin binding on SCD1 promoter, indicating that the reduction in SCD1 
expression upon DEPDC1A silencing is not entirely due to a less efficient SREBP1 
chromatin localization (Figure 24). 
 
  
 
Figure 24. SREBP1 binding on the SCD1 promoter upon DEPDC1A knock-down. Chromatin 
Immunoprecipitation assay of SREBP1 or IgG antibodies on SCD1 promoter in MDA-MB-231 cell line 
upon control or DEPDC1A silencing; the C region was analysed by qRT-PCR and the enrichment of 
immunoprecipitated chromatin is expressed as fold change with respect to the negative control IgG. Error 
bars indicate s.d of at least three replicates. Asterisk indicates p-value<0.05. 
 
Since DEPDC1A silencing seems to have only a weak effect on the SREBP1 binding on 
SCD1 promoter, we wanted to investigate the effect of DEPDC1A silencing on the 
SREBP1 transcriptional activity. To answer this question, we performed a luciferase 
reporter assay in MDA-MB-231 cells with a human SCD1-promoter luciferase reporter 
vector whose promoter sequence contains region C; to activate the SREBP1 
transcriptional activity we cultured the cells with media supplemented with either 10% 
Fetal Bovine Serum or 1% Lipid Depleted Serum and we measured the luciferase 
activity upon control or DEPDC1A silencing; as shown in Figure 25 and in line with 
literature data, when the cells were grown in lipid-free serum supplemented medium, we 
induced a SREBP1 activation and a consequent increase of the luciferase signal with 
respect to cells grown in full serum containing medium. Interestingly, when in the same 
conditions we silenced DEPDC1A, SREBP1 activation was abrogated to the same 
extent of SREBP1 silencing.  
These data point toward a role of DEPDC1A in regulating SREBP1 transcriptional 
activity on SCD1 promoter even without affecting its chromatin binding. 
  
Figure 25. DEPDC1A is required for the transcriptional activation of the SCD1 promoter by 
SREBP1. Luciferase assay using SCD1-luc reporter vector in MDA-MB-231cell line treated with the 
indicated siRNAs; cells were cultured in DMEM medium supplemented with FBS 10% or Lipid Depleted 
Serum (LPDS) 1% for 12h and the difference is expressed in fold change with respect to the siCTRL FBS 
10%. The firefly luciferase (luc) signal is normalized on luminescence levels resulting from coexpressed 
Renilla luciferase and is indicated in relative light units (RLU). Error bars indicate s.d of at least three 
replicates. Asterisk indicates p-value <0.05. 
 
To verify that this effect was not due to reduced SREBP1 protein levels, we monitored 
their variation in MDA-MB-231 cells in the different experimental conditions as above 
by Western blot analysis. As shown in Figure 26, the analysis indicates that SREBP1 
cleavage increases in cells grown with lipid-free serum, with a corresponding increase 
in SCD1 protein levels. Upon DEPDC1A silencing, the levels of SREBP1 remained 
unchanged, while SCD1 strongly decreased to levels comparable to those in full serum 
conditions. The silencing of SREBP1 effectively reduced both precursor and cleaved 
SREBP1 protein and impaired SCD1 expression as well. 
  
 
Figure 26. DEPDC1A silencing impairs SREBP1 transcriptional activity. Western blot analysis of 
SREBP1, DEPDC1A-V1 and SCD1 in lysates of MDA-MB-231 cultured in media supplemented with 
FBS 10% or Lipid Depleted Serum (LPDS) 1% for 12h upon control, DEPDC1A or SREBP1 silencing. 
HSP90 is shown as loading control. 
 
All these data indicates a role of DEPDC1A as transcriptional co-factor of SREBP1; it 
is required for SREBP1 chromatin occupancy, and its absence strongly impairs the lipid 
starvation-induced transcriptional activation of its target genes without modifying its 
protein levels.  
 
2.5 DEPDC1A is a transcriptional target of SREBPs transcription factor. 
Looking to the Western blot of Figure 26, it did not escape to our attention that lipid 
depleted serum-induced activation and subsequent silencing of SREBP1, respectively 
increased and abolished DEPDC1A protein levels. This could be explained by the fact 
that DEPDC1A might itself be a SREBP transcriptional target. To test this hypothesis, 
we measured transcript levels of DEPDC1A upon different siRNAs against SREBP1 
and SREBP2 with qRT-PCR. Interestingly, genetic ablation of both SREBPs 
significantly downregulated DEPDC1A messenger RNA, indicating that a 
transcriptional regulation by SREBPs exists (Figure 27a). Accordingly, also DEPDC1A 
protein levels were decreased following SREBPs RNA interference (Figure 27b). 
 
  
 
 
 
Figure 28. DEPDC1A is transcriptionally regulated by SREBP proteins. (a) qRT-PCR analysis of 
DEPDC1A transcript in MDA-MB-231 cells treated with the indicated siRNAs. Changes in gene 
expression are indicated as fold change with respect to siCtrl. Error bars indicate s.d of at least three 
replicates. Asterisk indicates p-value <0.05. (b) Western blot analysis of the cellular lysates of the 
experiments in (a);  SREBP1, SREBP2 and DEPDC1A proteins in MDA-MB-231 cells treated with the 
indicated siRNAs are shown. Actin is shown as loading control. 
 
Next, we sought to determine whether this is a direct transcriptional control, in other 
terms, if SREBP transcription factors directly bind to the DEPDC1A promoter. First, 
using a transcription factor binding site predictor software (Transfac®) we analysed the 
DEPDC1A promoter in order to verify the presence of a consensus sequence for 
SREBPs, and indeed we found a SRE element between -157/146nt upstream the TSS. 
Then, we performed ChIP experiments using anti-SREBP1, anti-SREBP2 or non-related 
IgG antibodies on the DEPDC1A promoter and indeed we obtained a strong binding 
enrichment in the region containing the SRE element, showing that SREBP 
transcription factors can modulate DEPDC1A expression directly by binding to its 
promoter (Figure 28). Altogether, the results of Figures 25-29 demonstrate that, in 
cancer cells, SREBPs induce their own transcriptional co-factor DEPDC1A, to enhance 
their transcriptional activity.  
 
a b 
 Figure 28. SREBP transcription factors bind to the human DEPDC1A promoter. ChIP assay of 
SREBP1, SREBP2 or IgG antibodies on DEPDC1A promoter in MDA-MB-231 cells upon control, 
SREBP1 or SREBP2 silencing; The region with the predicted SREBPs binding site was analysed by qRT-
PCR and the enrichment of immunoprecipitated chromatin is expressed as fold change with respect to the 
negative control IgG. Error bars indicate s.d of at least three replicates. Asterisks indicate p-value<0.05. 
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 DISCUSSION  
 
Currently only ~20% of patients with metastatic breast cancers respond to therapy ,a 
fact mainly ascribed to the intrinsic heterogeneity and plasticity that cancer cells 
display. This complexity, whose molecular underpinnings are only partially understood, 
is believed to underlie imprecise diagnoses and definition of metastatic risk, often 
leading to therapeutic decisions that fail to effectively tackle the disease (Santa-Maria 
and Gradishar, 2015). In addition, even after a primary response, metastatic breast 
cancers frequently become resistant to the therapy. For all these reasons it is evident that 
current classification and stratification methods are insufficient and that further research 
is necessary to unveil novel therapeutic vulnerabilities specifically directed to metastatic 
cells. 
 
In this thesis, we focused our attention on DEPDC1A, an oncogene that is almost 
undetectable in normal adult tissues, while it is overexpressed in many aggressive 
tumours and strongly associated with poor patients’ prognosis. In cancer cells, 
DEPDC1A has been mainly associated to proliferation and cell cycle (Huang et al., 
2017), as well as migration and invasion (Girardini et al., 2011), and our unpublished 
work demonstrated a role for DEPDC1A in promoting metastasis formation. Here, 
thanks to a high-throughput transcriptomic approach, we have unveiled a novel 
oncogenic function of DEPDC1A in a highly metastatic triple negative breast cancer 
model. In particular, DEPDC1A is responsible for the transcriptional induction of genes 
involved in the fatty acids biosynthesis pathway (ACLY, SCD1 and ELOVL6). Although 
a broader bioinformatic analysis in a transcriptomic dataset of metastatic breast cancers 
did not reveal a strong positive association between DEPDC1A and ACLY, SCD1 and 
ELOVL6 expression, an immunohistochemical staining in a set of 17 human breast 
cancer biopsies revealed a positive correlation between DEPDC1A-V1 and SCD1 
protein levels. This discrepancy could be explained by the fact that in the bioinformatic 
analysis we were not able to discriminate between the V1 and V2 isoform expression; 
since we have the evidence that the V1 isoform is the responsible for the induction of 
the lipid metabolic traits, the presence of the V2 could mask the transcriptional effect. 
The activation of this particular signature causes increased fatty acids accumulation, as 
demonstrated by increased lipid droplets content, and desaturation when DEPDC1A is 
 present. Lipid accumulation is a well-established phenotype in cancer cells which 
display a deranged lipid metabolism, and there is evidence that lipid droplets are 
required for cancer cell proliferation and aggressiveness (Koyzume and Miyagi, 2016; 
Tirinato et al., 2017), thus DEPDC1A, by activating lipogenesis, can influence cancer 
cell behaviour. 
Owing to the fact that these genes are regulated by the transcription factor SREBP1, a 
master regulator of fatty acid metabolism, and that we found a great overlap between 
DEPDC1A and SREBP1 regulated genes (data not shown), we have demonstrated that 
these two proteins cooperate in the expression of SCD1. Mechanistically, we have 
shown that DEPDC1A physically interacts with SREBP1a and SREBP2 but not with 
SREBP1c, the binding specificity towards SREBP1a could be explained by the fact that 
it has a longer N-terminal transactivation domain than SREBP1c that could endow the 
protein with more affinity for DEPDC1A. Moreover, we have demonstrated that 
DEPDC1A is recruited by SREBP1 on the SCD1 promoter, even if with a small fold 
enrichment with respect to IgG. This low enrichment might be explained by the fact that 
DEPDC1A does not bind directly the DNA, since it does not have a DNA binding 
domain. Nevertheless, the negative effect of DEPDC1A knockdown on SREBP1 
transcriptional activity is evident by the luciferase experiments. This result indicates 
that DEPDC1A can act as transcriptional cofactor of SREBP1 and regulating SCD1 
transcription. 
Fatty acid biosynthesis and, in particular, desaturation is instrumental for the induction 
of aggressive phenotypes, such as migration and invasion (Baenke et al., 2013); in fact, 
when we interfered with SCD1 activity (either by siRNA or enzymatic inhibition) in 
DEPDC1A overexpressing cells, we were able to abolish the DEPDC1A dependent 
migratory ability, demonstrating that, in this context, desaturation of fatty acids is a 
crucial step for this oncogenic activity and that SCD1 inhibition can be an interesting 
therapeutic option. 
Moreover, non-transformed breast cells (MCF-10A), which ectopically overexpress 
DEPDC1A and therefore have an increased SCD1 expression, become more sensitive in 
terms of viability to SCD1 enzymatic inhibition than empty-vector expressing control 
cells, indicating that lipid metabolic reprogramming induced by DEPDC1A might 
induce a potentially druggable dependency in cancer cells. 
Our results open up to further implications on the consequences of this aberrantly 
activated metabolic axis on cancer cells. For instance, SCD1 and ELOVL6 are relevant 
 for the maintenance of specific fatty acids compositions that is known to impact on 
stemness and membrane fluidity, both crucial properties of aggressive cancer cells 
(Zhang et al., 2007; Marien et al., 2016; Li et al., 2017). Moreover, fatty acid synthesis, 
desaturation and lipid droplets formation are key processes for Reactive Oxygen 
Species (ROS) scavenging and endoplasmic reticulum stress attenuation, particularly 
relevant in highly proliferating cancer cells (Matsui et al., 2012; Fu et al., 2012). 
Furthermore, SCD1 has been shown to be required for lipid modifications of signalling 
molecules, such as WNT, in order to sustain lung cancer stem cells (Rios-Esteves et al., 
2013; Noto et al., 2017). 
Another important implication involves ACLY, the rate limiting enzyme for the 
production of the cytosolic acetyl-CoA, which is not only required for fatty acid 
biosynthesis but is crucial also for acetylation of histones, thus potentially impacting on 
the cancer cells’ epigenetic landscape, which in turn underlies their plasticity and gives 
rise to adaptive clones that boost malignant progression (Kinnaird et al., 2016).   
In recent years, a growing body of evidence indicates that metabolic rewiring might 
represent a double edged sword, since cancer cells have been shown to depend on it, 
and, furthermore, it represents a possible way to discriminate the cancerous tissue from 
the normal counterpart (Hay et al., 2016), and many clinical trials based on the 
inhibition of metabolic targets are ongoing. 
Indeed, it is possible to target the transcriptional program activated by DEPDC1A. In 
particular here we have shown that SCD1 inhibition is able to dampen the oncogenic 
activity of DEPDC1A, but it does not affect normal cells. Pharmacological inhibition of 
SCD1 has been linked to toxicity to sebocytes in the skin and other tissues, but new 
inhibitors demonstrated to have no side effects towards non-transformed tissues 
(Theodoropoulos et al., 2016); with the rationale that cancer cells are strongly 
dependent on large amounts of lipids for biomass production and the synthesis of lipid-
derived signalling molecules and that fatty acid desaturation is a crucial step for red-ox 
balance and membrane fluidity (Koizume and Miyagi, 2016; Peck and Schulze, 2016), 
targeting SCD1 can be a valuable option, possibly in concomitance with other drugs 
that inhibit lipid metabolism, such as statins, in order to simultaneously abrogate two 
major processes of lipid metabolism that are crucial for metastatic cells. 
Interestingly, also ACLY and ELOVL6 are potential therapeutic targets, whose 
inhibitions has demonstrated to be promising both in vitro and in vivo. (Marien et al., 
2016; Kinnaird et al., 2016). 
 In sum, understanding the alterations of metabolic pathways that could endow cancer 
cells with metastatic proclivity is of crucial importance. With this thesis we provided a 
novel transcriptional mechanism that is able to induce a metabolic reprogramming in 
breast cancer, which sustains pro-metastatic phenotypes. More importantly, we showed 
that this altered fatty acid metabolism represents a possible vulnerability that could be 
potentially employed, in combination with other inhibitors and conventional therapy, to 
selectively dampen breast cancer invasiveness and dissemination. 
 
Data from our laboratory and other works indicate DEPDC1A as a cancer associated 
protein, and in our model we showed that it is induced by mutant p53. Previous work 
demonstrated that mutant p53 is able to induce lipid metabolism by direct interaction 
with SREBP2 and eliciting mevalonate pathway upregulation in triple negative breast 
cancer (Freed-Pastor et al., 2012). In this thesis we showed that another parallel 
mechanism is active to simultaneously upregulate fatty acid biosynthesis and enhance 
cancer aggressiveness, thus confirming that lipid metabolism upregulation is a crucial 
event in mutant p53 harbouring tumours. Interestingly, we evidenced that DEPDC1A is 
also a transcriptional target of SREBP1/2 making us hypothesize that SREBPs could be 
the transcription factors through which mutant p53 can induce DEPDC1A expression. 
Preliminary ChIP experiments indicate that SREBPs knockdown impairs mutant p53 
binding on DEPDC1A promoter (data not shown), thus confirming our hypothesis that 
mutant p53 and SREBPs cooperation is crucial for DEPDC1A overexpression. 
Moreover, in this context, since both mutant p53 and DEPDC1A are able to bind and 
regulate SREBPs activity, it is possible to hypothesize that these protein can constitute a 
ternary complex able to regulate lipid metabolism and experiments will be performed in 
this direction.     
Furthermore, we have evidence that DEPDC1A can be induced also in a mutant p53 
independent manner and that other oncogenes could mediate its activation (such as 
MYC and E2F; data not shown), indicating that it is a common target of different 
oncogenic programs. For these reasons, the study of DEPDC1A roles and regulation 
acquires a broader importance, not only for its overexpression in many cancers with 
different genetic background, but also because its inhibition is expected to be 
detrimental selectively for cancer cells.  
Interfering with DEPDC1A functions could be exerted in multiple ways, by using 
DEPDC1A as onco-antigen or by inhibiting its interaction with transcription factors. 
 For the first strategy, many efforts have been made to develop onco-vaccines against 
DEPDC1A. Some of them have already been used in combination with other cancer 
vaccines that have already been introduced within different clinical trials. The activation 
of the immune response towards cells overexpressing specific epitopes of DEPDC1A 
yielded interesting and promising results, indicating that this could be a real therapeutic 
strategy (Obara et al., 2012). 
Regarding the interference with the aberrant interaction with the transcription factor, a 
cell-permeable dominant negative peptide (11R-DEP: 611-628) that interferes with the 
DEPDC1A-ZNF224 complex has been produced, and its usage induces growth arrest 
and apoptosis in bladder cancer cells in a in vivo mouse xenograft model (Harada et al., 
2010). 
 
For future directions, taking advantage of high-throughput metabolomics analysis, our 
goal is to confirm and unravel the role of DEPDC1A in regulating lipid metabolism in a 
panel of different cancers. Secondly, it will be important to understand if, in vivo, 
DEPDC1A bearing tumours can be effectively targeted with SCD1 inhibitors, alone or 
in combination with other drugs, and if this could avoid metastasis formation.  
In parallel, we want to elucidate the mechanism through which DEPDC1A could 
influence SREBP1 activity in regulating SCD1, ACLY and ELOVL6 transcription. 
Furthermore, taking advantage of the RNA-seq analysis, other DEPDC1A regulated 
processes will be explored that could impinge on tumour progression and dissemination. 
Finally, it will be important to investigate the physiological functions of DEPDC1A and 
the biochemical activities of its domains in both normal and cancerous tissues. Of 
particular interest is the fact that its expression is kept at very low levels in normal adult 
cells and that it is instead aberrantly expressed in cancer; it will be intriguing to dissect 
the oncogenic signalling and the mechanisms that underlie DEPDC1A activation. All 
these data will give novel and interesting insights on the role of DEPDC1A in cancer 
cell biology.  
 
 
 
 
 
 MATERIALS AND METHODS 
 
Cell  culture 
MDA-MB-231 and MDA-MB-468 triple negative breast cancer cells, human  
embryonic kidney epithelial cells HEK  293T  and  293GP packaging cells have been  
maintained  in  culture  in Dulbecco’s modified Eagle’s Medium (DMEM) (Lonza) 
supplemented with 10% foetal bovine serum (FBS) (Euroclone) or lipoprotein depleted 
serum (LPDS) 1% (Biowest), penicillin (100 IU/ml) and streptomycin (100 IU/ml). 
MCF-7 breast cancer cells were cultured in EMEM medium (Lonza) supplemented with 
10% FBS, penicillin (100 IU/ml) and streptomycin (100 IU/ml). MCF10-A, a normal 
mammary cell line, was maintained in culture in DMEM/F12 (Lonza) medium 
supplemented with 5% HS (horse serum), penicillin (100 IU/ml) and streptomycin (100 
IU/ml) plus add of growth factor 10 µg/ml Insulin, 0.5  µg/ml Hydrocortisone and 20 
µg/ml Epidermal  Growth  Factor  (EGF). All cells were maintained at 37°C in 5% 
CO2. 
 
Transfections 
Cells were plated one-day before the transfection experiment. The appropriate plating 
density will depend on the growth rate and the condition of the cells. Cells that are 50–
80% confluency were used on the day of the experiment.   
For siRNA transfections, double-stranded RNA oligos (10  pmol/cm2) were  transfected 
with Lipofectamine RNAi-MAX (Life Technologies) in antibiotic-free medium 
according to the manufacturer’s instructions. Negative control siRNA was: AllStars 
negative control siRNA (Qiagen 1027281). 
DNA transfections were done with Lipofectamine LTX and Plus Reagent (Invitrogen) 
or Lipofectamine 2000 (Life Technologies) according to the manufacturer’s 
instructions. 
Lentiviral particles were prepared by transient transfection of HEK-293T cells with the 
packaging plasmids and with pLenti expression vector as indicated, using standard 
calcium-phosphate method. After 48 h incubation at 32°C the virus-containing  medium  
was filtered  (0,45  µm  filter),  supplemented  with  10%  FCS  and  8ug/ml  polybrene  
and added to  cells for 24h and then washed. Infected cells were enriched by drug 
selection (Puromycin, Blasticidin or Zeocyn, 2ug/ml each) for at least one week. 
 Retroviral packaging was made by calcium phosphate transfection of 293-GP packaging 
cells with the appropriate plasmids in combination with pMD2ENV coding for envelope 
proteins. After 8 hours, medium was changed with 10 ml of medium and cells incubated 
at 32°C. After 48-72h the virus-containing medium was filtered (0,45 µm filter) and 
supplemented with 10% FBS and 8ug/ml polybrene. The culture medium of target cells 
growing at low confluence (∼30-40%) was replaced by the appropriate viral supernatant 
and incubated at 32°C for 24h. Infected cells were selected with puromycin or Zeocyn. 
 
siRNAs  sequences are listed in the table below: 
 
siRNAs SEQUENCE (Sense, 5’-3’) (dTdT) 
siDEPDC1A (I) CCGUAGUCUAAGAUAACUA 
siDEPDC1A (II) CUAUCCAGUAAGGCUAUCA 
siSCD1 CUACGGCUCUUUCUGAUCAUU 
siSREBP1 (I) CCACUCCAUUGAAGAUGUA 
siSREBP1 (II) AUCUCUGAAGGAUCUGGUG 
siSREBP2 (I) UGAGUUUCUCUCUCCUGAA 
siSREBP2 (II) UCAGAAUGUCCUUCUGAUG 
siCTRL 
(QUIAGEN) 
UNKNOWN 
 
 
Plasmids 
pLenti-DEPDC1A-V1 was generated by subcloning DEPDC1A-V1 coding sequence 
from pCAGGSn- DEPDC1A-V1  kindly  provided  by  T.  Katagiri  in  pLenti  vector.  
pSR-shDEPDC1A plasmid was generated by cloning DEPDC1A (I) double stranded 
siRNA in pSuper Retro vector. The SREBP1a, 1c and 2 overexpressing vectors were 
obtained from addgene ( cod: #26801, #26802, #26807). 
 
RNA isolation and RT-PCR gene expression analysis.  
Total RNA was extracted using Trizol reagent (Invitrogen) according to the 
manufacturer’s instructions. Spectrophotometric method was used to determine the 
Concentration and purity of the RNA. For quantitative RT-PCR mRNA was reversed 
transcribed into cDNA with Quantitect Reverse Transcriptase Kit (Quiagen).  Real-time  
 PCR was carried out in triplicate with  SsoAdvanced TM SYBER GREEN Supermix 
(BioRad) and the CFX96 Real-Time System (Bio-Rad). Relative expression levels were 
normalized to controls by using the comparative Ct (ΔΔCt).  
The house-keeping gene Histone H3 was used to normalize the level of expression. 
 
PRIMERS SEQUENCE 
ACLY FW GACAGCACCATGGAGACCATGAAC 
ACLY REV GCCAATCTTAAAGCACCCAGGC 
DEPDC1A FW GATCTCCCTGAACCTCTACTTAC 
DEPDC1A REV CACTGGATCTATCTGAAACTGTG 
H3 FW GTGAAGAAACCTCATCGTTACAGGCCTGGT 
H3 REV CTGCAAAGCACCAATAGCTGCACTCTGGAA 
ELOVL6 FW CTCGAAATCAAGCGCTTTACAGA 
ELOVL6 REV AGGCAGCATACAGAGCAGAAA 
SCD1 FW CACTTGGGAGCCCTGTATGG 
SCD1 REV TGAGCTCCTGCTGTTATGCC 
 
Protein extraction and western blot analysis. 
For western blot analysis, cells were harvested and lysed in in 50 mM Tris-HCl pH 8.0, 
100 mM NaCl, 1 mM MgCl2, 1 mM EDTA, 1% Triton X-100 lysis buffer, 
supplemented with phosphatase and protease inhibitors (Sigma), and lysates were 
cleared by centrifugation. The proteins were separated using SDS-PAGE and blotted on 
nitrocellulose films; blocking was performed with 5% non-fat dry milk solution and the 
antibodies were incubated at 4°C over-night. Immunoreactivity was detected with anti-
mouse and anti-rabbit secondary Antibodies HRP labeled (Sigma) using ECL Plus 
Western Blotting Substrate (Pierce). 
For  Co-immunoprecipitation (Co-IP) experiments the cells were harvested and lysed in 
50 mM Tris-HCl pH 8.0, 100  mM  NaCl,  1  mM  MgCl2, 1  mM  EDTA,  1  %  Triton  
X-100,  10  %  glycerol supplemented with phosphatase and protease inhibitors, and 
lysates were cleared by centrifugation and pre-cleared with protein G-sepharose for 30 
min before O/N incubation with indicated antibodies. Protein G-sepharose, incubated 
overnight with 0.5 mg/ml BSA, was then added to the lysates and incubated for 1h. 
Beads were washed three times in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM 
EDTA, 0.1% NP-40. 
  
Antibodies 
Antibodies used for western blot: monoclonal anti-SCD1 (Ab-19862 Abcam), 
monoclonal anti-SREBP1 (Sc-13551 Santacruz), polyclonal anti-SREBP2 (Ab-30682 
Abcam), monoclonal anti-PLIN2 (ab181463 Abcam),  monoclonal anti-HA 
(11867423001 Roche) and monoclonal anti-HA Y11 (Sc-805 Santacruz), monoclonal 
anti-Flag M2 (F3165 Sigma), Actin (A-9718 Sigma) and HSP90 (Sc-13119 Santacruz). 
 
DEPDC1A antibody 
For DEPDC1A detection we have generated a functional antibody against DEPDC1A. 
To this end we have developed a polyclonal anti-DEPDC1 antisera immunizing rabbits 
against a C-terminal region of 190 amino acids common to the two DEPDC1A variants 
(DEPDC1A-V1 and DEPDC1A-V2). 
To generate the recombinant protein as immunogene, the plasmid pGEX 4T1 
expressing a common region of two variants of DEPDC1 (621–811 amino acids of 
DEPDC1-V1) and contained S-transferase (GST) gene from Schistosoma japonicum 
upstream of the MCS, was expressed in Escherichia coli  DH5α  cells. Overnight culture 
obtained were diluted 1:50 in Luria Broth (LB) medium containing ampicillin and 
grown at 37°C with shaking to obtain a 0.3-0.6 OD 600. Then, 1 mM IPTG was added  
to the culture for overnight induction at 30°C. Induced E. coli. cells were harvested by  
centrifugation then the cells were suspended in 10 mL of  cold lysis buffer (10 mL PBS, 
1% Triton-X, 1.5 % DTT (w/v), and protease inhibitors (Sigma), and then applied the  
suspension to sonication. Sonication was carriedmout using intensity input at 8 on a 
Misonix Sonicator for 10 sec for “pulse on” and 30 sec for “pause” for each cycle, 6 
cycles totally.  
The sonicated cell lysates were centrifuged at 10,000x rpm for 15 min at 4 °C and the  
supernatant were removed to a new tube and incubated with glutathione-sepharose 4b  
beads (GE Healthcare) overnight at 4°C according to the supplier’s protocol. The 
quality of the GST fusion proteins was verified by Comassie blue staining (0.2 % 
Comassie blue R-250, 40 % Methanol, 10% Acetic acid). To remove E. coli’s proteins  
as contaminations, each DEPDC1A fragment protein was cut and extracted from  
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) gel.  
The extracted  proteins were inoculated into rabbits, and subsequently the immune sera  
were purified on antigen affinity columns produced using the same antigenic peptide  
 cloned in pMal vector which encodes maltose-binding protein (MBP), according to the 
supplier’s instructions. 
 
Immunohistochemistry 
Tissues were either fixed in 10% neutral-buffered formalin, processed, and embedded in 
paraffin. Prior to immunostaining, tissue sections were deparaffinised, rehydrated, and 
heated in citrate buffer pH 6 for antigen retrieval. Sections were incubated in methanol/ 
30% H2O2 for 15 minutes at room temperature and blocked for 1-2 hours in normal horse 
serum/PBS/0.1 Tween solution (Vectastain). After the blocking, slides were incubated 
at 4°C with the indicated primary antibody, and then with the universal secondary 
antibody (Vectastain) for 45 minutes. To visualize the stain DAB solution (Vector 
Laboratories) was used followed by hematoxylin counterstaining. 
 
Chromatin Immunoprecipitation 
After specific treatments, MDA-MB-231 cells were cross-linked for 15 min with 1% 
formaldehyde, neutralized with 125 mM glycine pH2.5 and washed in PBS. Cells were  
scraped in PBS containing proteases inhibitors (protease inhibitor cocktail [Sigma], 1  
mM PMSF), and centrifuged at 4000 rpm for 10 min at 4°C.   
Cellular pellets were resuspended in hypotonic SDS lysis buffer (1% SDS, 10 mM  
EDTA, 50mM Tris-HCl pH 8.1, protease inhibitor cocktail [Sigma], 1 mM PMSF, 5  
mM NaF) and incubated for 10 min at  4°C. 
Chromatin was sonicated (power setting 5) with a Misonix Microson in 10'' bursts  
followed by 50'' of cooling on ice for a total sonication time of 2 min per sample. 
Samples were then centrifuged for 10 minutes at 13000 rpm at 4°C and the supernatants 
were transferred to new micro-centrifuge tubes and diluted 2 fold in ChIP dilution 
Buffer (0.01% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 500 mM 
NaCl). 
Chromatin was pre-cleared for 1 h at 4°C with protein A/G PLUS-Agarose (Santa  Cruz  
Biotechnologies) and at this step 10% of the samples was taken as Input. The 
immunoprecipitation was performed O/N at 4°C with 1 ug of the indicated antibodies 
on the remaining 90%. The day after the DNA/protein complexes were recovered with 
protein A/G PLUS-Agarose and washed sequentially with 1ml of Low Salt Wash Buffer 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 mM NaCl), 
1ml of High Salt Wash Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM 
 Tris-HCl pH 8.1, 500 mM NaCl) and 1ml of LiCl Wash Buffer (250 mM LiCl, 1% NP-
40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.1) and TE. RNase treatment 
was performed in TE for 30 min at 37°C. 
The proteinA-G agarose/ DNA/Histones complexes now were eluted in 1% SDS 0.1 M 
NaHCO3 solution vortexed and incubated for 15 minutes at room temperature with 
rotation, the samples were pelleted and the eluates were transferred into new micro-
centrifuge tubes. 20 ul of NaCl 5M were added to the eluate and the de-crosslinking was 
obtained by putting the samples at 65°C O/N. In parallel, inputs  were  treated in the   
same way. After phenol/chloroform extraction and ethanol precipitation samples were 
resuspended in H2O. Real-time qPCR was performed by using iTaq Universal SYBR 
Green Supermix  (BIORAD). Promoter occupancy was calculated as the fold increase 
of normalized immunoprecipitated chromatin over the control IgG with the  2–ΔΔCt 
method. 
The primers used are listed below 
 
 
 
Luciferase assays 
Luciferase assays were performed in MDA-MB-231 cells with the PGL3 vector as 
reporter with SCD1 promoter sequence. Cell lysates were analyzed using the Dual-
Luciferase Reporter Assay System (Promega). Luciferase reporters (300 ng cm−2) were 
transfected together with CMV–Renilla (30 ng cm−2) to normalize for transfection 
efficiency. 
PRIMERS SEQUENCE 
SCD1 PROMOTER REG A FW GCTAGGCAGTTCATGGGCA 
SCD1 PROMOTER REG A REV GGGAGGGAGAGTACAGGGTAA 
SCD1 PROMOTER REG B FW TTTCAACTTGGGGAGCTGGG 
SCD1 PROMOTER REG B REV CCTGGCTTTATGATACATTGTCCC 
SCD1 PROMOTER REG C FW CAGAGAGAAAGCTCCCGACG 
SCD1 PROMOTER REG C REV CTGTAAACTCCGGCTCGTCA 
SCD1 PROMOTER INTR 1 FW GCAGTTTTACCTCGGTCGGA 
SCD1 PROMOTER INTR 1 REV CGCTCCTCATAGCGAGTCTG 
DEPDC1A PROMOTER FW GTAGACCGCAGGAGGGAGAA 
DEPDC1A PROMOTER REV TGAATAGCATAGAGGGCTGCG 
 For luciferase assays in siRNA-transfected cells, siRNA transfection was achieved first 
and, after 48 h, transfection of plasmid DNA was performed and the cells were cultured 
in FBS 10% or LPDS 2% supplemented medium. 
 
Migration assays.  
For migration assay, transfected cells (1,5x105) were plated on 24 well PET inserts (8.0 
µm pore size, Falcon), according to the manufacturer’s instructions. After 18h, cells on 
the upper part of the membrane were removed with a cotton swabs and cells that passed 
through the filter were fixed in 4% PFA, stained with 0.05% crystal violet and counted.  
The data were represented as the means of at least three independent experiments with 
standard deviations indicated. Difference compared with the vector control. 
 
Viability assay. 
Cells (5*10^3 per well) were plated in 96-well plates and treated with SCD1 inhibitor 
(MF-438, Calbiochem) 2uM, Non treated cells and DMSO treated cells were used as 
controls. Cell viability was assayed with ATPlite (Perkin Elmer) according to the 
manufacturer’s instructions using the EnSpire Multilabel Reader (Perkin Elmer). 
 
Lipid droplets staining 
Lipid droplets staining was performed as following. Briefly, cells were fixed in 4% 
paraformaldehyde for 15 min, and then washed in PBS. Cells were incubated with 
LD540 fluorescent dyes (50ng/ml) for 20 minutes at room temperature. Nuclei were 
counterstained with DAPI. LD540 was kindly provided by Cristoph Thiele Group. 
The images were acquired through confocal microscopy, using a Nikon C1si confocal 
microscope, containing,457,477, 488, 514 argon lasers lines and 407, 561 or 640 nm 
diode laser. Light was delivered to the sample with an 80/20 reflector. The system was 
operated with a pinhole size of one Airy disk (30 nm). Electronic zoom was kept at 
minimum values for measurements to reduce potential bleaching. A 60X Oil Apo 
objective (with corresponding NA of 1.4) was used. Images were then processed for z-
projection by using ImageJ 1.50 (NIH, Bethesda, USA). 
For flow cytometry analysis of lipid droplets, the cells were harvested, pelleted and 
washed twice with PBS; then cells were re-suspended in 4% PFA and fixed for 20 
minutes. After that, the cells were washed with PBS and stained in a 1ug/ml solution of 
BODIPY 493/503, (Invitrogen) for 30 minutes.   
  
Analysis of FAMEs and desaturation. 
Fatty acid composition of the different test cells was analysed through a standard 
method based on saponification of lipids, methylation of fatty acids and gas 
chromatography/mass spectrometry analysis of the obtained FAMEs. Fatty acids were 
identified on the basis of their retention times and MS spectra and comparison with the 
gas chromatography/mass spectrometry library. The identification of FAMEs was 
obtained by comparison of sample mass spectra with those available in the Wiley 275 
libraries. Relative percentage for each component was calculated based on GC peak 
areas. 
 
Gene expression data analysis and Functional Analysis. 
 
Three biological mRNA replicates for each group (siControl or siDEPDC1A (I)) were  
performed on MDA-MB-231 cells. Total RNAs were extracted using Trizol reagent 
(Invitrogen), subjected to DNase-I (Ambion) treatment and RNAs were depleted of 
ribosomal RNA. Sequencing libraries for whole transcriptome analysis were prepared  
using ScriptSeq™ mRNA-Seq Library Preparation Kits (Epicentre® Biotechnologies,  
Madison, WI).  
RNA-seq was performed on an Illimina HiSeq 2000 station using standard conditions. 
Demultiplexed raw reads (fastq) generated from the Illumina HiSeq were checked using 
FASTQC tool and all samples passed the quality standards. We aligned them to the 
reference genome (UCSC-hg38) using STAR (Dobin et al., 2013), using recommended 
options and thresholds. FeatureCounts (Liao et al., 2014) was used to generate gene 
counts based on GENCODE 25. Differential gene expression analysis was performed 
using Edge R (Robinson et al., 2010).  
In order to identify the relationship between samples, the Euclidean distance between 
each pair of samples was calculated using the log-transformed values of cpm. Average 
linkage clustering was then used to generate a sample-to-sample distance heatmap, via 
the cluster3 software.  
Genes with FDR<0.01 and fold change > 0.5 or <-0.5 were selected as differentially 
expressed and used as input for the functional analysis. 
 Starting from the list of differentially expressed genes we performed functional 
enrichment analysis (Huang et al., 2009) and gene set enrichment analysis 
(Subramanian et al., 2005). 
Differentially expressed genes were further analysed using Ingenuity Pathway Analysis 
(IPA, Ingenuity® Systems, www.ingenuity.com). The prediction of the transcription 
factors and regulative molecules was obtained using the Upstream regulators function 
(IPA suite). For every upstream regulator an overlap p-value and a z-score are 
calculated: the p-value indicates the significance based on the overlap between dataset 
genes and known targets regulated by the molecule, while the z-score is used to infer the 
possible activation (z-score > 0) or inhibition (z-score < 0) of the molecule based on 
prior knowledge stored in the proprietary Ingenuity Knowledge Base. 
All statistical analysis and calculations have been performed in Rstatistical 
environment. 
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